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In the past 10 years, Genome-wide association studies (GWAS) have successfully 
identified thousands of loci that are associated with complex diseases and human 
traits. By aggregating samples from multiple populations across the world, a new 
wave of GWA meta-analyses have increased the statistical power to identify 
novel findings with smaller effect sizes. However, the amount of phenotypic 
variation explained by GWAS is much less than the total heritability estimated by 
twin and family studies. The missing heritability is believed to be caused by the 
following three reasons: i) classical approaches for meta-analysis are hampered by 
the presence of effect size and allelic heterogeneity; ii) the causal variants that 
fundamentally affect the diseases and traits are yet to be discovered; iii) the 
unexplored genetic impact of low-frequency and rare causal variants. To address 
these problems, we conducted four studies of trans-ethnic meta-analyses and fine-
mapping. We began with a systematic review to identify the most powerful 
statistical approach to accommodate the issue of effect size heterogeneity. To 
address the problem of allelic heterogeneity, we designed a novel strategy to 
assess regional association evidence which successfully captures the additional 
phenotypic variation explained by multiple causal variants. In order to locate the 
causal variants with more accuracy, we evaluated the merit of trans-ethnic fine-
mapping and accessed the impact of population-specific reference panel in 
identifying the functional variants that biologically affecting the phenotypes of 
interest. Last but not least, we extent to explore the feasibility of trans-ethnic fine-
mapping for rare causal variants by evaluating whether the conditions that have 
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CHAPTER 1 - INTRODUCTION  
1.1 Genome-Wide Association Study  
Genome-Wide Association Studies (GWAS) adopt a hypothesis-free agnostic 
approach to scan millions of single nucleotide polymorphisms (SNPs) across the 
whole genome to look for genetic risk factors that contribute to complex diseases 
and human traits. In the past ten years, GWAS have successfully identified more 
than 14,000 genetic variants in 2000 publications, according to a record by US 
National Human Genome Resource Institute, Oct 2014, 
(http://www.genome.gov/gwastudies/). The unprecedented success of GWAS is 
made possible primarily by two factors: i) the novel study design that subtly 
utilize the presence of linkage disequilibrium (LD) in the genome; and ii) the 
rapidly developed genotyping and sequencing technologies that accurately capture 
the genetic information. 
1.1.1 Linkage Disequilibrium and Indirect Association 
Linkage disequilibrium refers to the non-random association between alleles at 
contiguous loci within a population [1]. It arises from the joint inheritance of 
markers on the same chromosome within a family and recedes by recombination 
events. The set of alleles (SNPs on a single chromatid of a chromosome pair) 
jointly inherited from the same chromosome, thus associated statistically with 
each other are known as haplotype. Many factors including genetic drift and 
natural selection can enhance the strength of LD. Genetic drift results in the 
change in allele frequency due to random sampling. Natural selection protects 
mutations that in favor of survival and reproduction in a population and eliminates 
deleterious mutations that hamper them. Both events result in a higher probability 
for certain combinations of alleles to occur together than other combinations, thus 
enhance the strength of LD. Recombination events happen during meiosis, which 
randomly break apart the chromosome and reduce the strength of LD. As these 
factors are highly related to population size and evolutionary history, LD 
structures vary significantly across different populations. African-descent 
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populations have the shortest LD block since they are the most ancient 
populations and undergo more recombination events. In populations of non-
African ancestry, on the other hand, correlations between genotypes turn to 
extend over longer distances [2]. The international Human Haplotype Map Project 
(HapMap) [3] was designed to characterize the levels of LD in populations of 
European (CEU), Asian (CHB+JPT) and African (YRI) ancestries, and has since 
been expanded to include 11 human populations globally.   
In the presence of LD, contiguous SNPs that are highly correlated with each other 
are not necessary to be all assayed in the association studies. A carefully chosen 
subset of tag SNPs is informative enough to capture the genetic variation in a 
particular population. As such, the association signals identified from GWAS 
might not be the functional variants that ultimately lead to the phenotype, but 
surrogate tag SNPs that are highly correlated with the unassayed causal variants. 
This is known as the indirect association, which is one of the most important 
features of GWAS[4]. In the early stage, when genotyping technologies were 
limited to capture only a small set of genetic variants, the presence of LD makes 
GWAS implementable.  
1.1.2 Genotyping and sequencing Technologies  
To assay the genetic information of tag SNPs, chip-based genotyping arrays have 
been designed by two primary platforms: Illumina and Affymetrix. These two 
competing technologies adopt different forms of microarray, coupled with 
different selections of SNP content. Affymetrix used a random selection of SNPs, 
whereas Illumina used a set of tag SNPs reported in HapMap that are designed to 
maximize the genetic coverage in Europeans [5]. As such, the level of SNP 
sharing between the two platforms remained modest at best. In the past few years, 
technologies for measuring genomic variation have changed rapidly both in terms 
of SNP density on microarrays as well as the genotyping accuracy. The most 




NGS is the umbrella term used to describe a number of different high-throughput 
sequencing technologies that allow millions of reactions to be carried out in 
parallel. The fast and high-throughput features of the technology make it possible 
to examine the whole genome of human beings rather than a selected set of tag 
SNPs. In 2007, the 1000 Genomes Project (1KGP) was founded to perform low-
coverage whole-genome sequencing in major population  groups from Europe, 
East Asia, South Asia, West Africa and Americas[6]. Till the time of writing, the 
project has sequenced around 2500 individuals from 25 populations. It is 
anticipated to provide the most completed maps of genetic variation in diverse 
human populations globally.  
1.2 Genome-wide Meta-analysis  
The first wave of GWAS has been conducted mainly in homogenous populations. 
In its early stage, significant findings were made only in populations with 
European ancestry; gradually, more genetic variants in association with common 
diseases and human traits were unveiled from populations of African, Asian and 
admixed African-American ancestries. In order to boost the statistical power to 
identify additional genetic variants with smaller effect size, the second wave of 
GWAS have been concentrated on the genome-wide meta-analyses to combine 
samples from multiple studies globally.  
The standard meta-analysis takes a fixed-effects approach, which fundamentally 
assumes the same hypothesis in all studies. In particular, it requires a shared 
causal variant to be functioning with similar effect sizes across different studies. 
When the causal variant is not directly assayed (because of the indirect 
association feature), the same surrogate tag SNP is anticipated to be present in 
most if not all of the studies with similar effect sizes. While this strategy may be 
viable when combining data from homogeneous populations, this is unlikely to be 
fulfilled in a global meta-analysis at the presence of genetic diversity and 
biological heterogeneity.  
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1.2.1 Genetic diversity and biological heterogeneity 
First of all, a common disease or a human trait may be caused by different risk 
variants. For example, the high risk variant for cardiomyopathy at myosin binding 
protein C, cardiac (MYBPC3) only occurs in the Indian subcontinent with a 
frequency of ~4%, but is rare or absent elsewhere [7]. The presence of the causal 
variant diversity would result in the neglect of genuine genetic contributions to 
phenotypic variation when multiple studies are pooled together to boost the 
statistical power.   
Second, even if the same causal variant is functioning in all populations, many 
reasons can lead to the inconsistencies in effect sizes at GWAS assayed SNPs. 
Genuine variation of the underlying effects may exist at the same causal variant in 
different populations, as seen in the apolipoprotein E (APOE) ε4 allele for 
Alzheimeer’s disease [8]. Moreover, different study designs may undermine the 
consistency in phenotype definitions, which eventually result in the different 
effect sizes to be estimated from GWAS. In addition, difference in the LD 
structures can give rise to the effect size heterogeneity. Because of the indirect 
association, the causal variant itself may not be directly assayed on genotyping 
arrays. The effect size at the assayed tag SNPs depends highly on the strength of 
LD with the causal variant. Finally, Other than genetic exposures, environmental 
and lifestyle factors can also modify the impact of the genetic contributions to the 
phenotypes of interest [9].  
1.2.2 Statistical approaches for meta-analysis  
It is commonly agreeable that the aim of the global meta-analysis is to include as 
many studies as possible to increase the power to detect novel genetic variants, 
agnostic of the population ancestry or genetic background of each study. But the 
use of fixed-effects (FE) approach is likely to identify only the loci with 
homogeneous effect size that are present in most of the studies. Random-effects 
(RE) approach, on the other hand, assumes different effect sizes between studies 
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even under the null hypothesis of no associations, where all effect sizes are 
exactly zero. This implicit assumption makes the p-value overly conservative. 
To cope with heterogeneous effect sizes between studies, Han and Eskin 
developed an alternative random-effect model (RE-HE) that relaxing the 
conservative assumption under the null hypothesis by assuming a common true 
effect size of zero, while still allows the effect sizes to vary among studies under 
the alternative hypothesis [10]. In the presence of effect size heterogeneity, RE-
HE possesses a significant advantage in statistical power over the RE approach. 
Morris has also designed a Bayesian framework (known as “MANTRA”) to allow 
for effect size heterogeneity [11]. MANTRA fundamentally assumes that, studies 
from closely related populations are more likely to share a common true effect 
size; while the true effect size may vary across population clades. When the 
similarity in effect sizes is well captured by the relatedness between populations, 
MANTRA is found to possess higher statistical power over the traditional FE and 
the RE approaches. 
To address the challenge of causal variant heterogeneity, region-based association 
studies are coupled with meta-analysis, to extend the search for statistical 
evidence from SNP level to genes or biological pathways. Region-based 
approaches typically cluster SNPs based on their physical locations and estimate a 
collective effect incorporating all variants in a region. The advent of region-based 
meta-analysis enhances several advantages over SNP-based approaches. Firstly, it 
averts the massive multiple testing problem which compromises the ability to 
detect genetic variants with modest effect. Secondly, the findings from the region-
based approach is more biological meaningful. In fact, many of the findings from 
SNP-based approach require subsequent interpretation using a higher biological 
unit, such as genes or pathways [12]. Thirdly, the phenotypic variance explained 
by the region-based association results is remarkably higher than that have been 
explained by SNP-based association studies. 
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1.3 Trans-ethnic Fine-mapping 
The ultimate goal of GWAS is to identify causal variants that functionally affect 
the phenotype of interest to carry forward in the functional studies. However, 
because of the indirect association, association signals were mainly observed at 
proxy tag SNPs. Studies have shown that identifying causal variants can 
significantly increase the amount of variance explained, as has seen in the GWA 
studies of low-density lipoprotein cholesterol [13] and age related macular 
degeneration[14,15], where the variance explained doubled with the causal 
variants than the tag SNPs.  
Fine-mapping is the process to localize the underlying functional causal variants, 
or at least to narrow the genomic regions they reside, by closely examining a 
denser set of SNPs at GWAS susceptibility loci. Imputation technology is used to 
complement the genotyping microarrays with high-density reference haplotypes 
without introducing any additional costs. As introduced earlier, the international 
HapMap Project and the 1000 Genome Project (1KGP) have provided completed 
maps for human genomes in multiple populations. They can serve as good 
reference haplotypes for imputation to estimate genotypes for SNPs not directly 
assayed in GWAS, through exploiting LD patterns and haplotype frequencies.  
There are debates over the choice of reference panels. One side is in favor of the 
haplotype pool generated by HapMap and 1KGP (referred as “cosmopolitan 
reference panel”), with the belief that a more diverse collection of haplotype 
forms can increase the power of genotyping imputation [16]. The biggest 
advantage is that imputation can be carried out without additional cost since the 
cosmopolitan reference panels are publicly available. Moreover, the use of a 
common cosmopolitan reference panel can provide harmonized SNP contents 
when imputations are performed in meta-analysis of diverse populations. As a 
result, cosmopolitan reference panel is commonly adopted by GWAS and trans-
ethnic meta-analysis. In contrast, the other camp believes that reference panel 
must contain haplotypes drawn from the same populations to facilitate proper 
haplotype matching. Failure to do so may result in misidentification of causal 
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variants. Examples include an early study by Jallow and colleagues in localizing 
the haemoglobin S (HbS) variant in a malaria GWAS in The Gambia. The use of 
HapMap reference panel failed to isolate the causal variant while a targeted 
sequencing of an implicated gene in a handful of population-specific individuals 
managed to achieve so[17]. This example and many other studies have reported 
that population-specific reference panel can serve as a better reference panel to 
increase the imputation accuracy, even with considerably smaller sample sizes 
[17-19]. Thanks to the rapid development in sequencing technology, more 
completed and accurate population specific reference haplotypes are made 
available. For example, the recently completed Singapore Sequencing Malay 
Project (SSMP) [20] and Singapore Sequencing Indian Project (SSIP) [21] have 
performed deep whole genome sequencing in 96 healthy Singapore Malays and 
36 healthy Singapore Indians to capture the diverse genetic variations in 
Singapore population.   
One challenge faced by fine-mapping is that the extents of LD span longer ranges 
in populations of non-African ancestries. It leads to the identification of numerous 
perfect surrogates that are virtually indistinguishable from the causal variants 
[11,14]. Several reports have advocated the prospect of using different LD 
patterns intrinsic to multiple ancestries to overcome the challenge of long LD 
[11,22,23]. This is known as trans-ethnic fine-mapping, which is proved to be the 
most effective approach to narrow the regions harboring the causal variants by 
leveraging the differences in LD structures. A supportive example is a study 
conducted by Hughes and colleagues. They found a set of undistinguished SNPs 
in the region between the IL2/IL21 at chromosome 4q27 to be associated with 
lupus and a number of autoimmune and inflammatory diseases in samples drawn 
from populations from European ancestries; integrated with the association 
signals from African American ancestries localized the causal variants to two 
SNPs in IL21 region that affect the disease susceptibility [24]. However, 
identifying causal variants with certainty is proved elusive even with the trans-
ethnic fine-mapping as seen in a recent report for Type 2 diabetes [16].  
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1.4 Shift from Common to Rare Variants 
The majority of GWAS conducted in the early stage are designed based on a 
common disease-common variants model, which hypothesizes that complex 
diseases or human traits are largely affected by common variants (defined as 
variants with Minor allele frequency (MAF) > 5%), each has a small impact on 
the phenotype of interest [25-27]. However, the identified common variants 
turned to have small effect sizes and only a handful of them are the functional 
variants that actually cause the diseases. This is because a common variant takes 
many generations to accumulate its allele frequency; if it were deleterious with 
large effect, it would be quickly filtered out by the purifying selection. Besides, 
rare variants are more likely to be specific to one ancestry group because they 
have occurred recently and will thus not be shared across ethnicities.  
The second stream of genetic analyses target on low frequency and rare variants, 
with MAF falls between 1 to 5% and below 1% respectively. This type of variants 
can have large deleterious effects since they are more likely to be recent 
mutations that have yet been subjected to purifying selection. As such, the focus 
has since shifted to rare variants. Several studies have revealed the important roles 
of rare variants in contributing to the genetic risks underlying complex diseases. 
For example, Tang and colleagues reported a variant rs17863783 with a risk allele 
frequency of 0.025 in 5284 healthy controls and an odds ratio of 0.55 (95%CI = 
0.44-0.69, P = 3.3 × 10(-7)) for bladder cancer risk [28]; and a report by 
Nejentsev and colleagues that identified four rare variants with almost a two-fold 
reduction in Type 1 diabetes (T1D) risk through re-sequencing the IFIH1 gene 
that was initially implicated by T1D GWAS [29]. The latter study demonstrates 
the importance of surveying across the whole allelic spectrum: from common 
variants with small or modest effects, to low-frequency or rare variants with 
moderate to large effects (Figure 1), in order to understand the genetic 
































Figure 1 Identification of genetic variants by risk allele frequency and strength of 
genetic effect Genetic effect is compromised by the risk allele frequency. The detection 
of genetic variants concentrates within the range identified by diagonal dotted lines.  
Adapted from reference [30].  




CHAPTER2 – AIMS 
2.1 Study 1 - Comparing Methods for Performing Trans-Ethnic Meta-
Analysis of Genome-wide Association Studies  
Whilst early GWAS have primarily focused on genetically homogeneous 
populations, the next-generation genome-wide surveys are starting to pool studies 
from ethnically diverse populations within a single meta-analysis. However, the 
process is hampered by the presence of effect size heterogeneity. In this study, we 
aim to compare four different strategies for meta-analyzing GWAS across 
genetically diverse populations, to identify the most powerful strategy in adjusting 
effect size heterogeneity.  
2.2 Study 2 - A Statistical Method for Region-Based Meta-analysis of 
Genome-wide Association Studies in Genetically Diverse Populations 
SNP-based meta-analytic approaches are constrained by the assumption that the 
same causal variant is functioning in genetically diverse populations and the 
patterns of linkage disequilibrium between the causal variant and the directly 
genotyped SNPs are similar. The aim of this study is to develop a novel statistical 
method to perform region-based meta-analysis across diverse populations, so as to 
(i) accommodate the different patterns of LD 
(ii) integrate different SNP contents on various genotyping arrays; 
(iii) allow the presence of allelic heterogeneity and multiple causal variants 
2.3 Study 3 - Trans-Ethnic Fine-Mapping Using Population-Specific 
Reference Panels in Diverse Asian Populations 
Choice of reference panels is a key factor to determine the effectiveness of 
imputation based trans-ethnic fine-mapping.  In this study, we performed a 
systematic evaluation of the merit of trans-ethnic fine-mapping with GWAS data 




(i) assuming there exists a shared causal variant between diverse ancestry 
groups, can a trans-ethnic strategy locate this causal variant with more 
accuracy? 
(ii) is there any advantage to the use of population-specific reference 
panels in fine-mapping functional variants, above and beyond the 
current strategy of using cosmopolitan panel from Phase 1 of 1KGP 
that constitutes 1,092 individuals from 14 populations?  
2.4 Study 4 – Trans-Ethnic Fine-Mapping of Rare Causal Variants 
The focus for the next phase of GWAS has shifted to mapping low-frequency and 
rare variants.  However, it is not clear if the process of trans-ethnic fine-mapping 
be similarly applicable to identify the causal variants. In this study, we aim to 
explore the feasibility of trans-ethnic fine-mapping of rare causal variants by  
(i) investigating the conditions that have made the process possible for 
common variants,  






CHAPTER3 – COMPARING METHODS FOR PERFORMING TRANS-
ETHNIC META-ANALYSIS OF GENOME-WIDE ASSOCIATION 
STUDIES 
The content of this chapter has been published in Wang et al. 2013 [31] 
Introduction 
Genome-wide association studies have seen unprecedented successes at 
discovering novel genetic variants that influence the severity of different health 
outcomes in humans [32-34]. While many of the early findings have been made in 
homogeneous populations of European ancestry [35-38], recent reports have 
unveiled novel genetic associations discovered from populations of African 
[17,39-41], East Asian [42-44] and South Asian [45] ancestries. Most of the 
identified variants individually contribute a modest effect to the health outcome. 
To discern the association signals from the statistical noise that is inadvertently 
present from querying more than a million variants, these successful efforts 
typically meta-analyze several GWAS that have been performed in samples of 
similar ancestry. This increases the sample sizes while minimizing genetic 
heterogeneity across the study samples. The natural progression is to extend such 
meta-analyses to include samples from as many studies as possible, which can 
stem from different heterogeneous populations in the world.  
When used to perform such global meta-analyses, classical statistic approaches 
that assume either fixed- or random-effects at each SNP are constrained to the 
requirement that the same SNP has to be present across all the studies. In addition, 
fixed-effects models assume that the same SNP has to exhibit similar degree of 
association with the outcome of interest, in terms of the effect sizes, across most, 
if not all, of the studies. On the first requirement, it is common for the studies to 
be performed on different genotyping technologies, given the variety of 
commercial microarrays that differ in SNP density and placement. However, 
sophisticated and well-calibrated imputation procedures like IMPUTE [46] and 
MACH [47] has allowed the SNP contents of different studies to be harmonized 
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to the same resolution, with the use of reference data from the HapMap [46] or the 
1000 Genomes [6]. 
Addressing the heterogeneity in both effect sizes and association signals across 
diverse populations is non-trivial. Assuming a causal variant is actually present in 
all the different studies being assessed, there could still be several reasons 
underlying the heterogeneity of effect sizes detected in each of the study 
populations. Firstly, the study designs are often not identical, and subtle variations 
in phenotype definitions or measurements across studies can be an inadvertent 
source of heterogeneity. Secondly, as the causal variant is seldom directly queried 
in a genetic association study, variations in the degree and pattern of linkage 
disequilibrium between a SNP and the causal variant across studies can also 
introduce heterogeneity in the observed effect sizes. Finally, non-genetic 
exposures of different study populations are unlikely to be similar, and it is 
possible that environmental and lifestyle factors can modify the impact of the 
genetic contribution [48], resulting in the same causal variant exerting a different 
influence to the health outcome across the different populations.  
The point of global meta-analyses is to include as many studies as possible, 
agnostic of the population ancestry or genetic background of each study [41]. 
Taking the formal threshold of genome-wide significance (P-value < 5  10-8) into 
account, the use of fixed-effects methods (FE) will be methodologically bounded 
to locate only genetic effects that are strongly exhibited in most of the studies 
with a similar effect size. Although random-effects methods (RE) are specifically 
designed to handle heterogeneity, they tend to rely on a conservative assumption 
that the effect sizes are different across studies even under the null hypothesis of 
no association [10]. These standard epidemiological meta-analysis frameworks 
thus tend to overlook those signals that are either present in certain population 
clades only (which results in a significant down-weighting of the effect sizes 
towards the null of 0 by the populations not exhibiting the association), or where 
there is considerable heterogeneity in the effect sizes which increases the standard 
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errors of the estimated effect sizes and thus dampening the statistical evidence of 
the pooled association signal.  
To cope with heterogeneous effect sizes between studies, two new approaches for 
meta-analyzing GWAS data have been recently introduced. Han and Eskin 
developed an alternate random-effects model (RE-HE) that assumes a common 
true effect size of zero in all the studies under the null hypothesis and allows the 
effect sizes to vary among studies under the alternative hypothesis [10]. By 
relaxing the conservative assumption of RE under the null hypothesis, RE-HE has 
been reported to be more powerful than standard random-effects models and 
yields higher statistical power than fixed-effects models in situations where there 
exist inter-study heterogeneity in effect sizes. The second method by Morris 
(MANTRA) was specifically designed to perform trans-ethnic meta-analysis [11]. 
MANTRA adopts a Bayesian framework and assumes that studies from closely 
related populations are more likely to share a common true effect size, and the 
true effect size is allowed to vary across different population clades. When there 
exists a correlation between effect sizes and relatedness between populations, 
MANTRA has been reported to confer significantly higher power than both FE 
and RE.  
Here we perform a comparison of the four strategies for meta-analyzing GWAS 
across genetically diverse populations to gauge the relative performance in terms 
of sensitivity and specificity. We achieve this through a series of simulations 
where we intentionally: (i) vary the effect sizes present across ten populations in 
five different scenarios that mimicked different biological situations; and (ii) vary 
the number of studies investigated between 10 and 30. By identifying the 
approaches that are robust to inter-study effect size heterogeneity, we 
subsequently performed a trans-ethnic meta-analysis of seven GWAS in type 2 
diabetes and illustrate that these methods successfully identify bona fide 
associations that would otherwise have been missed by the classical FE and RE 
approaches.   
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Materials and Methods 
Fixed-effects meta-analysis (FE) 
FE assumes a common true effect size  for a particular allele at the SNP across 
all the studies, and the effect size of each study Ti is draw from a normal 
distribution with mean μ and variance σ2. Let vi be the variance of the ith study in a 
meta-analysis of K studies (although vi is an estimated value, it is treated as the 
true variance of study i in the meta-analysis), and let 1 ii vw
 
be the reciprocal of 
the variance, the inverse-variance-weighted effect-size estimator of the true effect 
















The variance of  FET  is estimated as   112ˆ  Ki iF w . Under the null hypothesis 
that there is no association, the test statistic can be calculated as   22 ˆ FFET  , 
which follows a Chi-square distribution with 1 degree of freedom.  
Random-effects meta-analysis (RE) 
RE assumes the true effect size for the ith study Ѳi is sampled from a normal 
distribution with mean μ and variance τ2. The between-study variance τ2 is 




























The between-study variance is estimated as  
c
KQ 1ˆ2    
when Q > (K – 1) or 0 when Q  (K – 1).  
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The inverse-variance-weighted effect size estimator is similar to that of the fixed-





























Under the null hypothesis that there is no association, the test statistic can be 
calculated as    222 ˆˆ  FRET , which similarly follows a Chi-square distribution 
with 1 degree of freedom. As the random-effects meta-analysis accounts for 
additional variability between the studies, the procedure is generally more 
conservative than the fixed-effects meta-analysis. 
The extent of inter-study heterogeneity can be assessed by comparing the test 
statistic Q against a Chi-square distribution with K – 1 degrees of freedom, which 
tests the null hypothesis that there is no variability in the distribution of the true 
effect sizes. 
Random-effects meta-analysis by Han and Eskin (RE-HE) 
RE-HE assumes that the true effect sizes are different among studies under the 
alternative hypothesis that a particular SNP is associated with the phenotype of 
interest in all studies. However, in the absence of any evidence of association, the 
true effect size should be zero in all the studies, and RE-HE adopts a hybrid 
approach that assumes there is no effect size heterogeneity (=0, τ2=0) under the 
null hypothesis. Taking a likelihood approach, the likelihoods under the null and 









































The maximum likelihood estimates for  and τ2, at the nth iteration from an EM 







































































The likelihood ratio test statistic is thus 



































When the number of studies is large, the test statistic asymptotically follows a 
mixture of a Chi-square distribution with 1 degree of freedom and a Chi-square 
distribution with 2 degree of freedom. When the number of studies is small, the 
tabulated p-values are provided by Han and Eskin, with reasonable accuracy for 
up to 10-8. For more significant p-values, the asymptotic p-value corrected by the 
ratio between the asymptotic p-value and the true p-value estimated at 10-8 is used.  
The effect-size estimate and its confidence interval in RE-HE are the same as 
those in RE. This is because RE-HE only modified the assumption under the null 
hypothesis. The effect size estimation is performed under the alternative 
hypothesis which is exactly the same as in RE.  
Bayesian approach meta-analysis (MANTRA) 
MANTRA assumes that studies from the same ethnic group are more 
homogeneous, thus they are likely to share the same effect size (denoted as 
population-specific effect i for the thi population cluster). But effect sizes vary 
among different population clusters.  
Let 0M denote the null model of no associations and 1M the alternative model in a 
Bayesian framework. Let T be the observed effect size from each study and s=v1/2 
the respective standard deviation, the evidence of association can be assessed by 
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where  is the model parameter including the population-specific effects β. The 






















sTf  . 
i is determined by the studies within the thi population cluster. Studies are 
assigned into population clusters based on the average allele frequency similarity, 
measured by the FST metric [52]. The author designed a Bayesian partition model 
to partition the studies, and to further calculate the likelihood under each model 
through a MCMC approach. The details of the method  can be found in the 
publication by the author [11].  
Simulation set-up  
Case-control data were simulated using the HAPGEN [53] program, with seed 
haplotypes from ten HapMap 3 populations (excluding ASW) and population-
averaged recombination rates from Phase 2 of HapMap [46]. The populations 
included in the simulation are listed below: 
CEU: Utah residents with Northern and Western European ancestry from the 
CEPH collection. 
CHB: Han Chinese in Beijing, China. 
CHD: Chinese in Metropolitan Denver, Colorado. 
GIH: Gujarati Indians in Houston, Texas. 
JPT: Japanese in Tokyo, Japan. 
LWK: Luhya in Webuye, Kenya.  
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MEX: Mexican ancestry in Los Angeles, California. 
MKK: Maasai in Kinyawa, Kenya. 
TSI: Toscans in Italy. 
YRI: Yoruba in Ibadan, Nigeria. 
The effective population sizes used in the simulations are: (i) 11,418 for CEU, 
GIH, MEX and TSI; (ii) 14,269 for CHB, CHD and JPT; (iii) 17,469 for LWK, 
MKK and YRI. Only SNPs that are not present on the Illumina 1M BeadChip, 
with minor allele frequencies of at least 1% in all populations are chosen as the 
causal SNPs in the simulations. For each simulation, we generated 30 studies, 
where each of the ten HapMap3 populations is used to simulated three studies, 
with 3,000 cases and 3,000 controls in each study. In the simulations to calculate 
the false positive rates, the allelic relative risk for every causal SNP in each 
population was set at 1.0 and the meta-analyses were performed at the causal 
SNPs. The false positive rates for FE, RE and RE-HE were calculated by counting 
the proportion of the causal SNPs which exhibited a meta-analysis P-value < 0.05. 
For MANTRA, the false positive rate was calculated as the proportion of the 
causal SNPs which exhibited a Bayes’ Factor of 105. To calculate statistical 
power, we considered five separate scenarios: (i) “All populations”, where all 30 
studies share the same allelic relative risk of 1.1 at the causal SNP; (ii) “Out-of-
Africa”, where all the non-African populations share the same allelic relative risk 
of 1.1 at the causal SNP, while the remaining African populations (9 studies from 
LWK, MKK and YRI) carry a null allelic relative risk of 1.0; (iii) “Europe and 
South Asia”, where only studies from CEU, GIH, MEX and TSI carry an allelic 
relative risk of 1.1, while the remaining 18 studies carry a null allelic relative risk 
of 1.0; (iv) “Effect size heterogeneity”, where the genetic effects are present only 
in non-African populations but the East Asian populations (9 studies from CHB, 
CHD and JPT) share an allelic relative risk of 1.2 at the causal SNP while the 
European and South Asian populations carry an allelic relative risk of 1.1; (v) 
“Environment modifier”, where the populations living in Europe and US (9 
studies from CHD, CEU and TSI) share the same allelic relative risk of 1.1 at the 
causal SNP, while the remaining populations carry a null allelic relative risk of 
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1.0. The last two approaches are meant to parallel the situation where different 
environmental exposures modify the influence of the genes on phenotype severity. 
The generated effect sizes are normally distributed about the respective means of 
1.0, 1.1 and 1.2 in the different scenarios (Figure 2). The power was calculated 
by counting the proportion of the causal SNPs with a meta-analysis P-value < 5  
10-8.  
Type 2 diabetes GWAS 
We considered seven genome-wide association studies in type 2 diabetes (T2D) 
from Singapore, Japan and the United Kingdom that have previously been 
reported either individually or in meta-analyses (Table 1). Japan: This consists of 
a T2D study across 931 cases and 1,404 controls sampled from 4 regions in 
Tokyo that have been genotyped on the Illumina HumanHap 550 BeadChip [43]; 
SCES: The Singapore Chinese Eye Study included 302 T2D cases and 1,089 
controls, out of a total of 1,952 Chinese subjects that have been genotyped on the 
Illumina Human610-Quad BeadChip; SIMES: The Singapore Malay Eye Study 
genotyped 3,280 Malay subjects in Singapore which included 794 T2D cases and 
1,240 controls genotyped on the Illumina Human610-Quad BeadChip [43,54]; 
SINDI: The Singapore Indian Eye Study genotyped 3,400 South Asian Indian 
subjects in Singapore, which included 977 T2D cases and 1,169 controls 
genotyped on the Illumina Human610-Quad BeadChip [45,54]; SP2-1M: The 
Singapore Prospective Study Program (SP2) which genotyped 5,499 subjects, of 
which 928 T2D cases and 939 controls were genotyped on the Illumina 
HumanHap-1M BeadChip [43,54]; SP2-610: Of the 5,499 SP2 subjects, 1,082 
T2D cases and 1,006 controls were genotyped on the Illumina Human610-Quad 
BeadChip [43,54]; LOLIPOP: This is a population-based cohort of South Asian 
samples that reside in West London and have all four grandparents born in the 
Indian subcontinent (which include India, Pakistan, Sri Lanka and Bangladesh), 
where 1,783 T2D cases and 4,773 controls were genotyped on the Illumina 
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Power and false positive rates 
We compared the performance of the two classical statistical methods for 
performing meta-analyses (FE, RE) to the two recently introduced strategies for 
trans-ethnic meta-analyses (RE-HE and MANTRA) using a series of simulations 
performed with HAPGEN using seed haplotypes from ten HapMap Phase 3 
populations (excluding the admixed population ASW). We simulated 3,000 cases 
and 3,000 controls for each of the ten populations in triplicate, yielding a total of 
30 studies in total and a possible sample size of 90,000 cases and 90,000 controls 
for the joint analysis of the 30 studies. In calculating the empirical false positive 
rates, we simulated 300,000 SNPs in each of the 30 studies under the null 
hypothesis of no association (see Materials and Methods for details). We varied 
the definition of statistical significance for P-value from 5  10-2 and 5  10-6 and 
from 100 to 105 for Bayes’ factor. We observed that the false positive rates for 
both FE and RE-HE are calibrated against the definition of statistical significance 
while the more conservative RE always yielded lower false positive rates 
compared to FE (Table 1). Owing to the nature that the Bayes’ factor criterion is 
not meant to be calibrated against the definition of statistical significance, we 
were unable to comment precisely on whether MANTRA was more conservative 
or liberal. However, we used the FE P-values obtained in our null simulations to 
calibrate the equivalent Bayes’ factor against the empirical false positive rates 
(Figure 3), and we observed that the Bayes’ factor threshold of 105 as 
recommended by the author of MANTRA [11] was expected to correspond to a P-
value threshold of 7.9×10-7. 
In order to perform a fair power comparison of the different methods for meta-
analysis, we have defined statistical significance as a P-value < 7.9×10-7 or a 
Bayes’ factor > 105 (see Table 2 for the same comparison at a P-value < 5×10-8 
and the equivalent Bayes’ factor > 106.1). We considered five scenarios involving 
the 30 studies in our simulation where the focal SNP was functional in: (i) all 30 
studies (“All populations”); (ii) studies from non-African populations; (iii) studies 
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from European and South Asian populations (“Europe and South Asia”); (iv) 
studies from non-African populations but with varying effect sizes according to 
population clades; (v) studies that originated from populations currently living in 
Europe or the USA (“Environment modifier”). In all the scenarios except (iv), a 
common effect size equivalent to an allelic relative risk of 1.1 was assumed at the 
functional focal SNP while a null relative risk of 1.0 for the populations where the 
focal SNP was simulated to be non-functional. In scenario (iv), we considered the 
situation where differential genetic effects existed in East Asian populations and 
European/South Asian populations: studies involving the former populations 
carried an allelic relative risk of 1.2 at each focal SNP; studies involving the latter 
populations carried an allelic relative risk of 1.1; and studies from the African 
populations carried a null relative risk of 1.0. We performed 2000 simulations 
under each scenario with 3,000 cases and 3,000 controls in each study.  
In all five scenarios, MANTRA was observed to yield the highest power out of 
the four approaches considered, while unsurprisingly RE yielded the lowest 
power (Figure 4, Table 2 and Figure 5). As expected, all four approaches 
performed similarly in the “All populations” scenario with power approaching 
100%, due to the large sample size of the joint analysis of 30 studies. When we 
reduced the number of studies in the meta-analysis to 10 and 20 respectively, the 
power decreased across all four approaches (Figure 6). In the remaining four 
scenarios where there existed heterogeneous effect sizes across the studies, RE-
HE and MANTRA consistently outperformed both classical meta-analysis 
methods of FE and RE. In particular, in the “Out-of-Africa” and “Europe and 
South Asia” scenarios where only 70% and 40% of the studies respectively were 
expected to exhibit the association, we saw considerable gains in power by 
MANTRA compared to the rest of the methods.  
As MANTRA clusters studies according to the genetic relatedness as measured by 
the allelic spectrum of the queried SNPs, we were keen to ensure that our 
simulations did not give MANTRA an unfair advantage by considering effect 
sizes that vary according to population clades. The fifth scenario introduced a 
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common effect size in two Caucasian populations (CEU and TSI) and a Chinese 
population (CHD), and this was meant to mimic the situation where a shared 
environment triggered the genetic impact of an otherwise neutral locus. We 
observed that in this scenario, all the methods had very low power below 10%, 
although both MANTRA and RE-HE continue to yield higher power than FE and 
RE models with MANTRA providing the highest power at 6.1%. 
Application to T2D data 
We applied the different meta-analysis approaches to combine the results from 
seven GWAS of type 2 diabetes in East, South-East and South Asian populations 
(Table 3). These included Chinese (SCES, SP2-1M, SP2-610)), Malay (SIMES) 
and South Asian Indians (SINDI) from Singapore, Japanese from Tokyo (Japan) 
and South Asian Indians residing in London (LOLIPOP). A total of 1,663,404 
autosomal SNPs were meta-analyzed, and the genomic control inflation factors of 
the FE and RE were 1.046 and 0.875 respectively. For MANTRA, we considered 
a Bayes’ factor threshold of 105 to define statistical significance (as recommended 
by the author), while for the remaining three approaches, we considered a P-value 
threshold of 7.9 10-7.  
All six association signals that were significant in the FE meta-analysis were 
similarly identified by RE-HE and MANTRA (Figure 7, Table 4). These 
included the well-established T2D loci such as CDKAL1, CDKN2AB, KCNQ1 and 
TCF7L2. In addition, RE-HE successfully located the HNF4A locus with stronger 
evidence (from 5.87  10-6 in FE to 3.26  10-7 in RE-HE). MANTRA similarly 
located HNF4A and further identified two more loci that did not achieve the 
definition of statistical significance by the other three methods. The reason that 
RE-HE and MANTRA performed better than FE at HNF4A was because of 
heterogeneous effect sizes at the index SNP rs4812829, where studies in East 
Asian populations (Japan, SCES, SP2-610, SP2-1M) exhibited consistent 
evidence of T2D with odds ratios around 1.1; The South Asian Indians (SINDI 
and LOLIPOP) exhibited stronger evidence of 1.2; but SIMES exhibited a 
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Table 1 False-Positive Rate of FE, RE, RE-HE and MANTRA at thresholds of 
increasing significance 
Threshold FE RE RE-HE MANTRA Threshold for MANTRA 
5.00E-02 4.97E-02 4.11E-02 4.97E-02 1.35E-01 Bayes’ Factor = 100 
1.00E-02 9.82E-03 7.63E-03 7.53E-03 9.07E-03 Bayes’ Factor = 101 
1.00E-03 9.81E-04 7.13E-04 8.26E-04 7.49E-04 Bayes’ Factor = 102 
1.00E-04 1.04E-04 6.86E-05 8.95E-05 7.75E-05 Bayes’ Factor = 103 
1.00E-05 2.98E-06 0.00E+00 8.95E-06 0.00E+00 Bayes’ Factor = 104 
5.00E-06 0.00E+00 0.00E+00 5.96E-06 0.00E+00 Bayes’ Factor = 105 
The left most column is the threshold for the false positive of FE, RE and RE-HE 
approaches, and the right most column is the threshold for the Bayesian approach. The P-




Table 2 Power comparison of the four methods under different simulation scenarios 
*Threshold for MANTRA at log10 (Bayes’ Factor) > 6.1 which is equivalent to a 
threshold of P-value < 5×10-8;  
§power for frequentist approaches at P-value < 7.9×10-7 which is equivalent to a threshold 














FE ( P-value < 5.0E-8 ) 0.997 0.857 0.304 0.958 0.001
RE ( P-value < 5.0E-8 ) 0.990 0.545 0.017 0.667 0.001
RE-HE ( P-value < 5.0E-8 ) 0.996 0.899 0.493 0.977 0.008
MANTRA ( log10(BF) >6.1*) 0.996 0.934 0.670 0.991 0.038
FE ( P-value < 7.9E-7§ ) 0.998 0.899 0.418 0.972 0.005
RE ( P-value < 7.9E-7§) 0.996 0.683 0.044 0.820 0.001
RE-HE ( P-value < 7.9E-7§ ) 0.998 0.930 0.605 0.988 0.017
MANTRA ( log10(BF) > 5) 0.998 0.954 0.724 0.994 0.061
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Japan 1 931 1,404 Illumina550 2,010,836 
SCES 2 302 1,089 Illumina610 2,464,566 
SIMES 3 794 1,240 Illumina610 2,081,354 
SINDI 4 977 1,169 Illumina610 2,082,842 
SP2-1M 5 928 939 Illumina1M 2,553,867 
SP2-610 6 1,082 1,006 Illumina610 2,467,633 





Table 4 SNPs exhibiting significant association signals (P-values < 5  10-8 in FE, RE-HE and Bayes’ Factor >= 105 in MANTRA) of seven type2 diabetes 
genome-wide association studies 
RSID CHR POS Effect Allele 
Other 









                    
rs9295474 6 20760696 G C 6.78 5.90E-08 9.67E-04 3.22E-09 CDKAL1 
rs1048886 6 71345910 G A 6.21 5.25E-02 3.57E-01 2.11E-06 C6orf57 
rs2383208 9 22122076 G A 7.87 6.35E-10 9.60E-05 2.95E-10 CDKN2AB 
rs7903146 10 114748339 T C 6.84 6.23E-09 6.23E-09 1.23E-08 TCF7L2 
rs2237896 11 2815016 G A 9.22 2.83E-11 3.56E-08 5.23E-11 KCNQ1 
rs11636554 15 75395802 G A 6.18 3.94E-08 3.05E-06 6.66E-08 PEAK1 
rs7178572 15 75534245 G A 5.69 1.10E-07 4.12E-06 1.82E-07 HMG20A 
rs676809 18 10677717 G A 5.35 4.07E-01 6.18E-01 1.50E-05 PIEZO2 
rs4812829 20 42422681 G A 5.18 5.87E-06 3.03E-02 3.26E-07 HNF4A 
The SNPs showing here are those with the highest association signal in each region. The regions that have been identified by FE, REHE and MANTRA are 
highlighted in grey in the respective columns. We have adopted a P-value threshold of 7.9  10-7 as this is empirically equivalent to a Bayes’ factor threshold 





It is increasingly common to combine genome-wide scans of the same outcome 
that have been performed in genetically diverse populations. We have examined 
the statistical power and false positive rates of four approaches for performing 
trans-ethnic meta-analysis of GWAS, and found the two recently introduced 
approaches by Morris (MANTRA) and Han and Eskin (RE-HE) are robust to 
heterogeneous effect sizes at a genuinely associated genetic locus that 
conventional epidemiological models assuming fixed- or random-effects will 
attenuate the overall signal, particularly when some studies fail to carry the 
association due to different study designs, environmental modification of genetic 
influence or the presence of diversity in the genetic architecture of the different 
populations. We further observed that MANTRA outperforms RE-HE in all the 
scenarios we examined, even when the associations are present in populations that 
do not belong to the same clade, which is an assumption adopted by MANTRA in 
clustering the studies. As with the fixed-effects model, the false positive rates 
displayed by RE-HE are calibrated against the definition of statistical significance. 
While we cannot directly evaluate the expected false positive rates for MANTRA 
as it relies on the use of Bayes’ factors, we observe that at the recommended 
Bayes’ factor threshold of 105, the false positive rate out of 300,000 simulations 
under the null remained at zero. These methods are readily available as two 
computationally efficient stand-alone linux software “MANTRA” and “metasoft” 
respectively.  
Inter-study heterogeneity can pose a more serious challenge in meta-analyses of 
genetic association studies, compared to traditional non-genetic epidemiological 
meta-analyses. The additional complexity due to diverse genetic architectures of 
the different ancestries which affect SNP tagging efficiency, as well as the poorly 
understood implications of environmental modifiers in modulating the influence 
of the functional gene variants, imply that the observed effect sizes across trans-
ethnic populations are unlikely to be homogeneous all the time. Current genome-
wide meta-analyses have fundamentally relied on using fixed-effects models to 
locate genetic associations, which have significant limitations. First, does this 
mean that these meta-analyses may be consigned to identify only the variants that 
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carry homogeneous effect sizes that are present in most, if not all, of the studies? 
Second, given the tendency to “regress towards the mean” when estimating the 
pooled effect size, is it likely that the reported effect sizes from meta-analyses will 
be under-estimates of the true effect sizes, thus inadvertently discounting the 
amount of heritability explained in certain populations? We stress that this should 
not be confused with the “winner’s curse” where the observed effect size of the 
first study may be an over-estimate of the true effect size. Importantly, classic 
genome-wide meta-analyses using fixed-effects models may be missing out on 
explaining more of the genetic heritability because fundamentally this may be an 
inappropriate tool to locate the genetic variants? Given the stringent criteria that 
have been imposed on GWAS reports, having a few studies exhibit null 
associations in the meta-analysis (due to reasons as discussed above) may just tilt 
the balance for some variants to be dropped from the follow-up replication 
experiments.  
One drawback of MANTRA is the lack of proper effect size estimation for the 
meta-analysis. While it provides an estimate of the effect size at every SNP for 
each study and an overall Bayes’ factor as the combined association signal, it does 
not estimate a combined effect size from the joint analysis of all the studies even 
in the absence of heterogeneity across studies. In theory, one can use the posterior 
probabilities generated from MANTRA to partition the studies into different 
clades, and a clade-specific effect size can be estimated manually. Under the 
assumption of no effect size heterogeneity in the null hypothesis, the RE-HE is 
more powerful than the naïve RE meta-analysis but it gives the same effect size 
estimate as the RE because the effect size estimation is performed only under the 
alternative hypothesis where both RE and RE-HE carry the same assumption. 
Under the assumption of no effect size heterogeneity in the null hypothesis, the 
RE-HE is more powerful than the naïve RE meta-analysis but it gives the same 
effect size estimate as the RE because the effect size estimation is performed only 
under the alternative hypothesis where both RE and RE-HE carry the same 
assumption.  
In summary, there is growing interest and need to perform global meta-analyses 
as different research groups extend their collaborations to include GWAS from 
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multiple heterogeneous ethnicities. Having the right analytical tools for 
performing such trans-ethnic meta-analyses is vital, as conventional fixed-effects 
method used in classical epidemiology will likely locate gene regions where the 
associations have already been uncovered in bulk of the studies. In such meta-
analyses, there is almost no control of the experimental designs of the different 
studies, and this is likely to affect the ability to discover a genuine association. 
One convenient example is the FTO gene locus for T2D which was not detected 
in case-control designs that matched samples by obesity status (e.g. FUSION 
[55]), since the contribution of FTO to T2D was via increasing obesity propensity. 
The HNF4A locus provides another useful and validated example that an 
unguided fixed-effects meta-analysis of studies from diverse ethnicities can omit 
genuine biological signals. We have assessed the performance of four methods to 
perform trans-ethnic meta-analyses and showed that the Bayesian approach 
MANTRA is the most robust method in accounting the various situations of effect 




CHAPTER4 – A STATISTICAL METHOD FOR REGION-BASED META-
ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IN 
GENETICALLY DIVERSE POPULATIONS  
The content of this chapter has been published in Wang et al. 2012 [56] 
Introduction 
Remarkable achievements have been made in large-scale genetic studies of 
common diseases and complex traits [32,33]. The identification of variants in the 
human genome that are convincingly associated with different phenotypes has 
mainly been carried out in individuals of European descent, although increasingly 
studies involving non-Caucasian samples from diverse population groups have 
been published or are currently being conducted. Genome-wide meta-analyses 
(GWMA) involving tens of thousands of samples have extended the success in 
allowing novel variants with smaller effect sizes to be discovered [36,37,57-59]. 
Despite these triumphs, these findings really account for only a small fraction of 
the total disease heritability [34], suggesting undiscovered genetic mechanisms 
may be responsible or alternative methods to analyze these data may be necessary 
to address the missing heritability. 
Current implementation of GWMA requires the same SNPs to display consistent 
evidence of phenotypic association across multiple populations. This implicitly 
assumes that across these populations, (i) the same causal variant is present; (ii) 
the LD pattern between the causal variant and the assayed SNPs is similar; and (iii) 
the effect sizes observed at the assayed SNPs are consistent [23,60]. Random-
effects methods for combining data across studies do not utilize information from 
neighboring SNPs that may present concurring evidence of disease association in 
different studies, and often have the tendency to weaken association signals [60]. 
SNP-based meta-analyses also require the same SNPs to be genotyped in all the 
populations, although this requirement can apparently be addressed by imputation 
strategies that effectively standardize the SNP content across different studies 
[47,61,62] (Figure 9). However, imputation does not always present an effective 
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significance is thus more challenging, and larger sample sizes in non-European 
studies and meta-analyses of ethnically mixed populations are required to 
compensate for variations in LD patterns from European populations [17,65]. 
Instead of seeking individual variants that display convincing evidence of 
phenotypic association across multiple populations, a more realistic scenario is 
perhaps to look for genomic regions with consistent clustering of SNPs exhibiting 
moderate signals in these populations. 
In this paper, we propose a novel paradigm for interrogating genetic data for 
disease association given either a dichotomous or a quantitative outcome. Our 
method works by quantifying the degree of over-representation of associated SNPs 
in a pre-defined genomic region, given a specific definition of statistical 
significance. Through an Eigen-decomposition of the matrix measuring the LD 
between every possible pair of SNPs in the region, the effective number of 
independent SNPs as well as the number of independent SNPs exhibiting evidence 
of phenotypic association can be evaluated (Figure 10). The regional evidence of 
phenotypic association is thus quantified as the extent of over-representation of 
independent associated SNPs against the effective total number of independent 
SNPs in the region. This approach can be applied in a genome-wide fashion by 
considering moving windows of a fixed length within a population. In addition, 
this presents a natural framework for integrating the results from multiple studies 
in a region- based genome-wide meta-analysis, where we can sum up the number 
of independent signals and independent SNPs in each region across the different 
studies, and to calculate a single regional P-value for this meta-analysis by 
quantifying the joint extent of over- representation. This framework also allows a 
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lIn order to evaluate the effective number of ‘independent’ SNPs in each genomic 
region, we perform an Eigen-decomposition of the L × L symmetric correlation 
matrix M between the L SNPs with entry mij denoting the linkage disequilibrium 
in directional r2 between  the ith and the jth SNP, where the direction is determined 
by the sign of D’. Here we assume the minor allele frequencies of all L SNPs are 
at least 1%. The resulting eigenvectors effectively represent mutually independent 
contributions in explaining the variance in the correlation matrix, and each 
eigenvector is given as a linear combination of SNPs that are in at least some 
degree of LD. The SNP loadings of each eigenvector measure the extent each SNP 
contributes to the eigenvector, and the relative loadings between the SNPs for each 
eigenvector provide a surrogate for the degree of correlation between the SNPs. 
The L eigenvectors thus represent independent sources of information from all the 
SNPs in the window, and the number of eigenvectors Ntotal that cumulatively 
accounts for % of the variance can be determined as   li ii L1 %minarg  , for 
1  l  L and where i represent the eigenvalue corresponding to the ith 
eigenvector ei. Let w denote a vector of length L with the wi entry corresponding 
to one if the observed P-value for the ith SNP is < Pcrit, and zero otherwise. 
Suppose eij denote the jth component in the ith eigenvector, then the corresponding 
component in the ith scaled eigenvector represented by e’i is  Lj ijij ee 1/ . The 
effective number of independent SNPs that exhibit P-value < Pcrit is thus 
calculated as   totalNi ihit ewN 1 ' . 
The regional evidence for the extent of over-representation of SNPs with P-values 
< Pcrit is calculated as the upper-tailed P-value of the exact Binomial test for 
observing hitN  out of Ntotal SNPs when the success probability is given as Pcrit. 
However, as hitN  can be a non-integer, we estimate the P-value associated with 
hitN by linear interpolating between the P-values obtained for the floor and ceiling 
integer values of hitN , or equivalently Pfloor + (Pceiling – Pfloor)  ( hitN  –  hitN ), 
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Type 2 diabetes datasets 
We applied our region-based meta-analysis approach to combine the evidence 
from three separate genome-wide surveys of type 2 diabetes in the Chinese, South-
East Asian Malays and Asian Indians from Singapore. Results from each 
individual survey and the SNP-based meta-analysis have been reported elsewhere 
[54]. Briefly, the Chinese GWAS examined 2,010 cases and 1,945 controls (post-
QC) that were typed on a mixture of Illumina610 (1082 cases/1006 controls) and 
Illumina1M arrays (928 cases/939 controls). The corresponding numbers for the 
Malay and Indian GWAS were 794 cases/1,240 controls and 977 cases/1,169 
controls, and these were all genotyped on the Illumina610 arrays. A genome-wide 
region-based meta-analysis was first performed between the Chinese data that 
were genotyped on the two arrays to yield a single set of findings for the Chinese 
experiment. The three experiments for the different population groups were used 
as discovery cohorts for a region-based meta-analysis with a window size of 
250kb and a sliding gap of 50kb such that two consecutive windows have a 200kb 
overlap. We also performed a gene-based meta-analysis across 30,037 genes 
identified from the hg18 version of the TransMap UCSC gene mapping, with each 
window spanning a 100kb flanking buffer from the start and end coordinates of 
each gene. A pathway analysis was also performed for 212 pathways in the KEGG 
database [66-68] (www.genome.jp/kegg/pathway.html). Each gene (inclusive of a 
25kb flanking buffer) in a particular pathway was considered as a distinct window, 
except for genes within 50kb of each other which we merged as one discrete 
window. The intra-population evidence for a pathway was calculated from the 
summation of the effective number of independent significant and total SNPs 
across the windows. The P-value threshold (Pcrit) was set at 0.01. We identified 
any genomic region that exhibited P-value < 0.001 in at least two populations from 
the region-based and gene-based analyses. This is an additional criterion to ensure 
that at least two populations are contributing to the observed signals, given the 
fundamental strategy of our approach is to identify genomic regions that are 
associated with the outcome in multiple populations. We excluded any regions that 
are known to carry copy number changes since estimation of LD is likely to be 
inaccurate in these regions. For the pathway analysis, we identified a pathway that 
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exhibited P-value < 0.05 in at least two populations. To avoid artificial signals of 
disease association that were the results of erroneous genotype calling, genotyping 
quality was visually ascertained in each cohort for every SNP located in the 
discovered regions from the region-based analysis. To validate the findings, 
similar analyses were performed on the type 2 diabetes data from Phase 1 of the 
Wellcome Trust Case-Control Consortium [65]. Calculation of LD in each of the 
discovery and validation cohorts was performed with 500 control samples from the 
respective study. 
Software implementation 
The method described in this paper is implemented in three separate C++ 
programs: (i) regionalP for performing genome-wide region-based analysis; (ii) 
regionalP-gene for performing gene-based analysis; (iii) regionalP-pathway for 
performing pathway-based analysis. The programs are available from 
http://www.statgen.nus.edu.sg/~software/regionalP.html 
Results 
Power and false positive rates 
We compared our method for regional analysis against standard SNP-based 
analyses with (i) only the genotyped SNPs or with (ii) the full set of SNPs after 
imputing against reference panels from phase 2 of the HapMap (HapMap2). In the 
meta-analysis combining the results from all three populations, the power of the 
region-based strategy was similar to that from a meta-analysis of the imputed 
SNPs (Figure 12). This was significantly higher than the power from the meta-
analysis of only the genotyped SNPs. The false positive rates of all three meta-
analytic approaches were smaller than 5%, although the region-based approach 
had a near-zero false-positive rate when we imposed an additional restriction 
requiring at least two populations to exhibit P-values of less than 0.001 in the 
same region (Table 5). At a genome-wide significance of 10-8, this additional 
restriction resulted in only a marginal decrease in statistical power, although this 
decrease was more substantial at less stringent significance thresholds. 
Investigating the sensitivity of our method by the allelic spectrum of the simulated 
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causal variants in CEU, we observed the region-based approach was less powerful 
in identifying low-frequency causal variants (MAF of causal variant < = 5%) but 
was marginally more powerful for common causal variants (MAF of causal 
variant > 5%, see Figure 12). 
We also explored the performance of the three approaches in the presence of 
allelic heterogeneity, defined as having different causal variants in the same gene 
or genomic location across different populations. Specifically, we performed 
another series of simulations assuming two different causal variants in CEU and 
JPT+CHB, while allowing YRI to carry either of the two possible causal variants. 
Our simulation explicitly selected causal variants that are at least 20kb away but 
within 50kb of each other. The region-based approach significantly outperformed 
both SNP-based approaches in the meta-analyses across CEU and JPT+CHB, 
particularly at lower Type I errors and when LD between the two causal variants is 
low (Figure 13). When the LD between the two causal variants is high (r2 > 0.8), 
there is almost no difference in the results of the SNP-based meta-analyses of all 
three populations at higher Type I errors as compared to the power observed in our 
earlier simulations with only one causal variant. This is reassuring since we expect 
the two causal variants to behave as effectively a single variant when the LD is 
high. However, the low power experienced by the SNP-based methods in the 
presence of two separate causal variants reflects the inadequacy of SNP-based 
approaches for integrating data across diverse populations, and the greatest merit 
of the region-based approach is in the presence of allelic heterogeneity between 
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Table 5 False positive rates in the meta-analyses 




(MAF  5%) 
Common SNPs 
(MAF > 5%) 
Region-based 4.96 4.12 5.07 
Region-based with 
restriction 0.04 0.00 0.05 
Genotyped SNP-
based 
3.84 2.75 3.98 
Imputed SNP-based 1.98 1.89 1.99 
 
The false positive rate is defined as the percentage of the 5,000 simulations where there is 
at least one SNP/region displaying a meta-analysis Bonferroni-corrected P-value of < 
0.05 within 150kb of either flanks of the causal variant, though the Region-based with 
restriction meta-analysis adopts additional criteria to identify regions exhibiting P-value < 
0.001 in at least two populations. The Bonferroni correction for the SNP-based analyses 
multiplies the P-value for each SNP by the total number of SNPs that are analyzed, while 
the Bonferroni correction for the region-based analysis multiples each region-based P-
value by the total number of regions. In principle, the false positive rates for the imputed 
SNP-based analyses are likely to be under-estimates since the Bonferroni correction is 





Application to T2D data 
We applied our method to perform region-based, gene-based and pathway-based 
meta- analyses in three independent genome-wide studies of type 2 diabetes (T2D) 
involving Chinese, Malays and Asian Indians in Singapore. This was performed 
across all the autosomal chromosomes within each of the three GWAS in a 
hypothesis-generating fashion, where for the region-based analyses we considered 
sliding windows of 250kb each with a sliding distance of 50kb such that every pair 
of consecutive windows overlapped by 200kb. About half of the Chinese samples 
were genotyped on the Illumina1M array, while the remaining half of the Chinese, 
the Malay and the Indian samples were genotyped on the Illumina610 array. 
Results of the SNP-based meta-analyses using both the genotyped SNPs and the 
imputed SNPs have been reported elsewhere [54]. Briefly, none of the SNPs 
achieved genome-wide significance in the meta-analyses, although variants in 
CDKAL1 and HHEX/IDE/KIF11 displayed moderate evidence of T2D association 
in at least two of the three populations. In particular, variants in CDKAL1 were 
found against a genomic background exhibiting substantial LD variations between 
the populations [69]. 
The genome-wide meta-analysis with our region-based method identified five 
regions exhibiting P < 0.001 in at least two of the three populations (Table 6). 
Other than the region on chromosome 6 that encompassed CDKAL1, the other four 
regions did not emerge in the SNP-based meta-analyses [54] (Table 7). In the 
replication experiment with the WTCCC data, two of these five regions displayed 
strong evidence of regional association (P < 10-4) in the case-control T2D GWAS, 
which included the stretch on chromosome 6 encompassing CDKAL1 and the 
region on chromosome 3 between 21.73Mb and 22.13Mb that encompassed 
ZNF659. Suggestive corroborative evidence (P < 0.05) from WTCCC were also 
seen in the region on chromosome 2 that spanned the STK39 gene and the region 
on chromosome 14 containing the genes GNG2 and NID2. There was no evidence 
of regional association in the WTCCC for the remaining region on chromosome 20 
spanning STX16 and NPEPL1. 
Remarkably, all five regions have been previously implicated in diabetes, obesity 
or other cardiovascular biomarkers. The convincing signal for the region 
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encompassing CDKAL1 is consistent with established findings for T2D [55,70-74], 
while ZNF659 has been associated with young-onset type 2 diabetes in American 
Indians [75]. The STK39 gene has been consistently reported to harbor variants 
implicated in hypertension and in obesity and diabetes-related rodent quantitative 
trait loci [76]. Previous pathway analysis has identified the G-protein GNG2 to be 
associated with type 1 diabetes [77], suggesting a serotonin modulating 
mechanism that is similarly relevant in the etiology of type 2 diabetes. Variants in 
STX16 have also been re-ported to significantly slow the reversal of insulin-
stimulated glucose transport [78,79], a biological mechanism that is highly 
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1.20  10-5 
11.1 173 1.56  
10-6 
56,609,795 56,859,795 0.9 25 0.294 
Genomic regions identified by the region-based analysis, with the discovery mechanism based on three genome-wide association studies conducted in Chinese, 
Malays and Asian Indians in Singapore. Validation of the regions that emerged was performed on the type 2 diabetes case-control study from Phase 1 of the 
Wellcome Trust Case-Control Consortium (WTCCC).   
1 The start and end positions of the genomic region containing consecutive windows with P < 0.001 in at least two of the populations (in bold). The start and 
end positions of the top 250kb window are shown in brackets. Subsequent columns show the evidence for the discovery populations in the top window.  
2 The three discovery populations abbreviated: C – SP2 Chinese, M – SiMES Malays, I – SINDI Indians.  
3 Effective number of independent SNPs with P < 0.01 after accounting for LD. 
4 Effective number of independent SNPs across the region after accounting for LD. 
5 The start and end positions of the genomic region containing consecutive windows with evidence of validation (defined as P < 0.05), with the start and end 
positions of the top 250kb being shown in brackets. Subsequent columns show the evidence for WTCCC1 in the top window. For regions without any 250kb 
windows displaying P < 0.05, the best window in that region is shown instead.
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Table 7 Results of the SNP-based analyses for each of the three discovery populations and also for the meta-analysis 
In each region, the SNP exhibiting the strongest evidence is displayed. 
 
Chr Start Stop postion rsID SP2‐610 SP2‐1M SP2 combine p‐value SP2 combine OR SIMES SINDI Meta‐analysis Odds Ratio
2 168,408,674 168,858,674 168835009 rs1448829 4.80E‐05 8.63E‐01 4.89E‐03 0.8712265 1.24E‐02 4.67E‐01 2.70E‐01 0.9624245
2 168,408,674 168,858,674 168550292 rs12986593 4.75E‐02 2.93E‐02 3.35E‐03 1.2034914 6.66E‐01 7.27E‐01 3.62E‐02 1.0993474
2 168,408,674 168,858,674 168632317 rs4668014  1.42E‐03 7.45E‐01 1.17E‐02 1.1376889 5.12E‐04 9.00E‐01 8.70E‐01 1.0062575
2 168,408,674 168,858,674 168652010 rs11891632 3.13E‐02 6.78E‐01 6.38E‐02 1.1124454 5.12E‐02 5.80E‐04 5.77E‐02 1.0841736
3 21,736,044 22,136,044 21973519 rs1684524 1.26E‐02 8.45E‐01 4.45E‐02 1.5178577 8.37E‐01 6.87E‐01 3.45E‐01 1.1194122
3 21,736,044 22,136,044 21936270 rs1486333 1.64E‐01 3.14E‐04 1.28E‐01 0.9315197 8.37E‐03 6.48E‐01 9.84E‐01 1.0006789
3 21,736,044 22,136,044 22094224 rs4858356 8.56E‐01 7.63E‐01 7.70E‐01 1.0710731 1.64E‐03 7.19E‐01 2.17E‐01 1.0976422
3 21,736,044 22,136,044 21794472 rs2593324 8.98E‐01 1.30E‐01 3.45E‐01 0.9539118 5.00E‐01 1.26E‐02 1.94E‐02 0.9241339
6 20,594,609 20,894,609 20802862  rs2206734 4.68E‐04 2.56E‐02 4.50E‐05 1.2079713 4.23E‐01 9.57E‐02 3.28E‐05 1.1505583
6 20,594,609 20,894,609 20634995  rs4712523 2.45E‐03 1.09E‐02 7.75E‐05 1.1984318 5.09E‐01 4.33E‐03 5.38E‐06 1.1618693
6 20,594,609 20,894,609 20765542  rs6905281 7.22E‐02 7.17E‐01 3.54E‐01 0.4902118 2.73E‐02 4.92E‐01 1.05E‐01 0.7555437
6 20,594,609 20,894,609 20679113 rs4429936 9.06E‐01 7.07E‐01 8.63E‐01 0.9905743 1.77E‐01 3.41E‐04 1.71E‐01 1.0506065
14 51,355,752 51,755,572 51645261 rs10151177 8.86E‐03 9.05E‐02 2.08E‐03 0.7978463 2.69E‐01 2.41E‐02 9.54E‐01 1.0026201
14 51,355,752 51,755,572 51714478 rs1956264 7.34E‐01 3.27E‐06 5.85E‐04 1.1784373 3.64E‐01 4.44E‐01 1.25E‐01 1.0520246
14 51,355,752 51,755,572 51562817 rs2993998 6.94E‐01 9.75E‐01 7.56E‐01 0.9857651 4.25E‐05 4.50E‐01 1.40E‐01 1.0488298
14 51,355,752 51,755,572 51390853 rs2749870 2.24E‐01 6.59E‐01 5.61E‐01 1.0302266 2.86E‐03 4.84E‐04 4.41E‐01 1.0268038
20 56,559,795 56,859,795 56612722 rs1575802 7.96E‐04 1.00E‐01 1.41E‐01 0.8044956 2.86E‐01 2.65E‐02 1.44E‐01 0.9077273
20 56,559,795 56,859,795 56610594 rs6128397 8.80E‐02 3.51E‐03 1.13E‐03 0.8603747 2.33E‐01 3.85E‐01 1.68E‐02 0.9263088
20 56,559,795 56,859,795 56728535 rs12625855 4.04E‐01 7.96E‐01 4.40E‐01 0.9190362 3.47E‐02 2.88E‐02 2.22E‐01 1.1122356




The scale of genome-wide meta-analyses with diverse European and non-
European populations is expected to increase dramatically given the popularity of 
genome-wide designs in studying the genetic etiology of common diseases and 
complex traits. This however increases the challenge of accommodating varying 
patterns of LD that may exist between genetically diverse populations, which can 
compromise the ability to reproduce the association signals from surrogate 
markers that are correlated to the unobserved functional polymorphisms. We have 
introduced an alternative strategy for combining the evidence across different 
populations that is robust to dissimilar patterns of LD surrounding a bona fide 
association signal. The approach is applicable to both case-control studies or in 
association studies of quantitative traits. Our method has also been shown to 
perform comparably to imputation-based meta-analysis, except it relies on 
available genotype information from the experiment without requiring additional 
reference data from appropriately matched populations. In the presence of allelic 
heterogeneity, our approach outperforms both SNP-based approaches using either 
genotyped or imputed SNPs. The application of the region-based method to three 
genome-wide surveys in T2D resulted in the discovery of novel and established 
regions that are subsequently validated with data from the WTCCC. 
The region-based approach relies on the elegant application of the concept of 
statistical significance in evaluating a genomic region for evidence of trait 
association. For example, under the null hypothesis that the region is independent 
of the phenotype, we expect 5% of the SNPs to be statistically significant by 
chance when adopting a P-value threshold of 5%, if indeed all the SNPs in this 
region are mutually independent. If this assumption of mutual independence is true, 
an over-representation of statistically significant SNPs in this region constitutes 
evidence that this region is associated with the phenotype, with the extent of over-
representation indicating the strength of the evidence. This is analogous to the use 
of 5  10-8 as the definition of genome-wide significance for assessing the likely 
authenticity of single markers. LD between the SNPs can confound the 
measurement of over- representation, since this can either inflate the number of 
significant signals which increases false positives, or produce an inflated estimate 
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of the total number of SNPs which decreases statistical power. The eigen-
decomposition of the LD matrix allows the effective number of independent SNPs 
to be estimated and consequently, also the effective number of independent 
association signals that are statistically significant. By surveying the same 
genomic region across different independent populations, the same statistical 
framework can be extended to consolidate the evidence from multiple populations, 
simply by summing the effective number of independent SNPs and signals across 
these populations and assessing the evidence for an over-representation of 
significant signals. This provides a simple but yet effective solution to combining 
the results from experiments that use different genotyping platforms. By searching 
for the same regions rather than the same SNPs to emerge in the different GWAS, 
inter-population variation in LD patterns between the assayed SNPs and the causal 
variant is expected to have lesser impact on the sensitivity of our approach. 
One feature of our method is the ability to sharpen the association evidence in 
regions containing multiple weak signals across different ethnic groups. These 
signals may be weaker as a result of SNP ascertainment biases in the design of 
genotyping arrays, resulting in weaker LD between the assayed SNPs and the 
causal variants. The current definition of genome-wide significance excludes many 
potential signals to be considered in a bid to protect against the abundance of false 
discoveries that is associated with testing in excess of a million hypotheses. This 
poses a significant challenge to genome-wide studies and GWMA in populations 
with short LD, such as African populations [63,80], as it is less likely for variants 
to be in sufficient LD to exhibit statistical evidence stronger than the stringent 
threshold. Furthermore, the greater genetic diversity that is common of such 
populations means it is not immediately straightforward to compensate for the 
lower LD by increasing the effective sample size through a meta-analysis of 
several populations. Our method thus provides a viable solution within a sound 
statistical framework to exploit and combine the evidence from SNPs that are 
weakly associated with the phenotype. 
The application of analytical methods that investigate regions in the genome rather 
than relying on individual SNPs is not a new concept. Neither is implementing a 
statistical strategy to estimate the effective number of independent association tests 
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in the presence of LD. Numerous approaches have in fact been introduced to 
address the issue of multiple testing in the presence of correlated SNPs [81-87]. 
However these methods either assign the most significant SNP-based evidence as 
the statistical evidence for the set of loci [83], or do not explicitly incorporate the 
association evidence in adjusting for the effective number of tests [82,84-87]. A 
recent region-based approach adopted a more sophisticated approach that borrows 
information from surrounding SNPs, although it tends to rely on heuristic 
measures like the proximity to specific genomic features (e.g. known genes, 
evolutionarily conserved regions, haplotype blocks) for defining SNP clusters [88]. 
In our opinion, the imputation frameworks that MACH [47] and IMPUTE [62] 
are built on provide a more natural way to incorporate information from 
surrounding SNPs without relying on pre-defined features that may not adequately 
account for the correlation between SNPs. We thus benchmarked our method 
against the performance of the imputation-based approach, which has become the 
strategy of choice in recent genome-wide studies. More importantly, none of the 
previous region-based approaches provide a natural solution to integrate the 
evidence across multiple genome-wide studies in a meta-analysis, nor adequately 
manage the complexity due to allelic heterogeneity. 
We have proposed a novel and powerful strategy for querying the genome for 
genotype- phenotype associations that realistically manages the challenges 
imposed by the fundamental design of genome-wide studies and in combining 
several such studies from diverse populations. We envisage this approach has the 
potential to be further developed for burden-related tests of rare or low-frequency 
variants across multiple heterogeneous populations, which is an emerging issue 
given the increasing popularity of exome-sequencing experiments across 
numerous traits. 
Supplementary Material 
SNP-based inverse variance meta-analysis 
We performed a fixed-effects inverse-variance meta-analysis in order to combine 
the evidence from the three population panels in our simulations. As the SNP-
based meta-analysis necessarily requires the same SNPs to be assayed across all 
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three populations, this has been performed in two settings: (i) on only the SNPs 
that are found in all three genotyping platforms (Affy500, Affy6 and Illum1M), 
which we subsequently defined as SNP-based meta-analysis; (ii) on all the SNPs 
that are present after imputing against the appropriate HapMap haplotype 
reference panels, which we subsequently defined as imputation meta-analysis.   
Simulation set-up for calculating power and false positive rates 
In order to evaluate the performance of the region-based meta-analysis, we 
simulated case-control data using the HAPGEN program [53] with reference data 
from phase 2 of the International HapMap Project [46]. We randomly selected 
5,000 SNPs that are present in all three HapMap population panels but not on any 
of the popular genotyping platforms from Affymetrix and Illumina (Affymetrix 
500K, Affymetrix 6.0 and Illumin1M) as causal variants. For each causal variant, 
we simulated 1000 cases and 1000 controls in each of the CEU, JPT+CHB and 
YRI panels by assuming a multiplicative disease effect equivalent to an allelic 
relative risk of r at the minor allele of the causal variant, with r = 1 for assessing 
false positives and r = 1.5 for evaluating statistical power (see Supplementary 
Material for power simulations when r = 1.3, Figure 14). Genotype data for SNPs 
located within 750kb on either flanks of the causal variant were simulated in each 
HapMap panel. To mimic the scenario where experiments involving different 
populations utilized different genotyping technologies, we thinned the simulated 
CEU case-control genotypes to only the SNPs that are located on the Affymetrix 
500K array. The JPT+CHB and YRI data were reduced to the SNPs found on the 
Illumina 1M and Affymetrix 6.0 arrays respectively. To compare against the ideal 
scenario that appropriate population-specific haplotype panels are available for 
imputation against, we ran IMPUTE [62] on the thinned genotype data from each 
population with the corresponding HapMap reference panel although we excluded 
the simulated causal variant to represent an incomplete reference panel. This 
statistically infers the genotypes of the removed SNPs. Frequentist tests for 
additive disease association are performed with SNPTEST on the thinned 
genotype data and the imputed SNPs, with analyses of the latter incorporating the 




recommended effective population sizes of 11,418, 14,269 and 17,469 were 
adopted for CEU, JPT+CHB and YRI respectively during the HAPGEN 
simulations and the imputations with IMPUTE [62]. 
In each simulated 1.5Mb region, assessment of power and false positive rates 
considered only the 150kb region on either flanks of the simulated causal variant. 
We performed the regional analysis with 5 windows of size 100kb such that every 
consecutive pair of windows overlapped by 50kb. The power of the regional 
method is defined as the proportion of the 5,000 simulations where a statistical 
significance greater than the assumed type 1 error is observed in at least one of 
the 5 windows. For the SNP-based analyses where we considered: (i) only the 
genotyped SNPs; and (ii) the imputed SNPs, in this 300kb region, the power for 
each of the two scenarios is defined as the proportion of the 5,000 simulations 
where a statistical significance greater than the assumed type 1 error is observed 
in at least one of the genotyped/imputed SNPs.  
Power simulations with allelic heterogeneity between populations 
In order to assess the statistical power of the three approaches for identifying a 
locus in the presence of allelic heterogeneity across the populations, we 
performed another series of simulations with two causal variants where the 
positions of the causal variants are between 20kb and 50kb apart. We selected 
3,000 pairs of SNPs that are present in all three HapMap population panels, 
subject to the condition that the minor allele frequencies of both SNPs were at 
least 10% in all three panels. Based on the LD between the two SNPs estimated in 
CEU, we binned each simulation into one of four LD bands: (i) 0  r2   0.1; (ii) 
0.1 < r2   0.3; (iii) 0.3 < r2  0.8; (iv) 0.8 < r2  1, such that the size of each bin is 
approximately equal. For each pair of SNPs, we simulated 1000 cases and 1000 
controls, where: (i) the first SNP is the causal variant in the CEU simulations; (ii) 
the second SNP is the causal variant in the JPT+CHB simulations; (iii) there is an 
equal chance that either of the two SNPs is designated as the causal variant in the 
YRI simulations. This is meant to simulate a situation of allelic heterogeneity 
between Caucasian and East Asian populations, while the African population is 
equally likely to possess either of the two causal variants. The overall set-up of 
the design and power analyses is similar to the single causal variant simulations 
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described above, with an additional meta-analysis being performed between the 
CEU and JPT+CHB data only to reflect the statistical power of the meta-analysis 
in the presence of allelic heterogeneity.  
Comparison of reference panels for LD estimation  
It was previously established that sample size can affect LD estimation, with the 
general observation that smaller sample sizes can result in an inflation of LD 
[17,89]. It is also of interest to investigate the impact of using dense genotype data 
from publicly available resources like the International HapMap Project [46] and 
the Singapore Genome Variation Project (SGVP)[69] for calculating LD in the 
region-based analyses. We performed a series of comparisons to assess the use of 
different sets and sizes of genotype data for estimating LD in our region-based 
analysis. Specifically, we performed seven genome-wide analyses with the SP2 
Chinese samples that were genotyped on the Illumina610 array, using the 
following sample sets to estimate LD during the region-based analysis: 
(i) 500 randomly chosen SP2 control samples from the GWAS (which is the 
selection used in all the T2D analyses in the main text); 
(ii) 96 Chinese samples from the CHS panel in the Singapore Genome 
Variation Project; 
(iii) 60 YRI samples from Phase 2 of the HapMap;  
(iv) 60 randomly chosen SP2 control samples from the GWAS; 
(v) 100 randomly chosen SP2 control samples from the GWAS; 
(vi) 250 randomly chosen SP2 control samples from the GWAS; 
(vii) 1,000 randomly chosen SP2 control samples from the GWAS.  
 
We observed that calculating LD with a small set of genotype data (60 SP2 
samples) or with an inappropriate population panel (60 YRI from HapMap2) 
resulted in findings that can be quite different from using a larger set of 
population-specific genotype data (500 SP2 samples, see Figure 15). Specifically, 
when the genotype panel was smaller or inappropriate, we observed regions 
exhibiting stronger statistical evidence than when a larger genotype panel from 
the specific population was used. However, there did not seem to be any large 
64 
 
differences when the size of the genotype panel was in the order of a hundred and 
beyond. We similarly observed no significant differences when an appropriate 
reference genotype panel of 96 Chinese samples from the SGVP was used.  
Comparison of window sizes in the regional analyses 
For each region in our power simulations, we also assessed the performance of the 
region-based approach with different window sizes of 50kb, 150kb, 200kb, 250kb 
and 300kb in addition to the 100kb window size that was reported in the main text 
(see Figure 16). Consecutive windows of 50kb did not contain any overlapping 
region, whereas for window sizes of 100kb to 300kb, the starting positions of 
every consecutive pair of windows differed by 50kb. As before, statistical power 
is quantified by the proportion of the 5,000 simulations where a statistical 
significance greater than the assumed type 1 error is observed in: (i) at least one 
of the regions in the region-based analysis; (ii) at least one of the actually 
genotyped SNPs; (iii) at least one of the imputed SNPs, within 150kb of either 
flanks of the causal variant. As the region considered in each simulation spans 
only 300kb, there were thus: (a) 6 windows of 50kb; (b) 5 windows of 100kb; (c) 
4 windows of 150kb; (d) 3 windows of 200kb; (e) 2 windows of 250kb; and (f) 1 
window of 300kb.  
Our analyses of the simulated data after thinning to the SNP contents of the 
common genotyping platforms (Affymetrix 500K, Affymetrix 6 and Illumina 1M) 
suggest that window sizes between 150kb and 250kb yield the highest statistical 
power, while window sizes that are overly small (50kb) or large (300kb) tend to 
yield marginally lower power.   
Comparison of eigenvalue threshold in the regional analyses  
To evaluate the effect of the eigenvalue threshold in the region-based analysis, we 
performed a power comparison using different eigenvalue thresholds at 0.8, 0.85, 
0.9 and 0.99 in addition to the 0.95 threshold that was reported in the main text 
(see Table 8).  
Our power analyses indicate there are consistent increments in the power across 
different level of type I errors as the eigenvalue threshold increase from 0.8 to 
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0.99. However, this comes at the expense of higher false positive rates. For 
example, at the eigenvalue threshold of 0.99, the false positive rate for region-
based analysis can be as high as 9.7%.  
Comparison of over-representation P-value threshold in the regional analyses 
To investigate the relationship between the over-representation P-value threshold 
and the power of the region-based analysis, we performed a power comparison 
using different P-value thresholds at 0.05, 0.01 and 0.001 (see Table 9). 
Our power analyses indicate that the region-based method reaches its highest 
power when the over-representation P-value threshold is set to be 0.01, although it 
is comparable with the power at P-value threshold of 0.001 at type I error of 10-8. 
The associated false positive rates are all within the expected 5% when the P-
value threshold is set at either 0.01 or 0.001. However, the false positive rates are 
higher when the P-value threshold is set at 0.05. Thus to compromise between 
false positive rates and statistical power, our empirical analyses have adopted a P-
value threshold of 0.01.  
Power differences with different simulated relative risk 
To investigate whether there is a change in the relative power trend between the 
three meta-analysis approaches in detecting effect sizes smaller than a relative 
risk r = 1.5, we performed another series of power simulations assuming a relative 
risk of r = 1.3 (see Figure 14). The set-up is exactly identical as described in the 
Methods (in the main text) and in Supplementary Methods 1.1, except that the 
relative risk has been changed to r = 1.3.   
Our power analyses indicate there is an overall reduction in power across all the 
three methods considered: (i) a meta-analysis across the genotyped SNPs found in 
all three arrays; (ii) a meta-analysis across the imputed SNPs found in all three 
populations in HapMap; (iii) a region-based meta-analysis using the genotyped 
SNPs, as compared to the power observed at a relative risk of 1.5. However, the 
trend of the relative power between the three methods remains similar to the 
simulation findings when the relative risk is 1.5. The power of the region-based 
strategy was similar to that from a meta-analysis of the imputed SNPs (see Figure 
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14) at genome-wide significance, and this was significantly higher than the power 
from the meta-analysis of genotyped SNPs. The additional restriction requiring at 
least two populations to exhibit regional P-values of less than 0.001 in the same 
region yielded marginally lower power at a genome-wide significance of 10-8, as 
compared to the unrestricted approach.    
Quantifying inter-population variation in regional LD patterns 
Variation in patterns of LD around the causal variants can affect the performance 
of the three approaches. The extent of LD variation between two populations was 
quantified by the standardized varLD metric [90]. Briefly, windows of 50 
consecutive SNPs present in both populations were considered. In each 
population, the signed r2 between every possible pair of SNPs in each window 
was calculated as a measure of the direction and strength of the LD between the 
two SNPs. An Eigen-decomposition was performed on each of the two resulting 
50  50 symmetric matrices, and the extent of LD variation in each window 
between the two populations was quantified as the sum of the absolute difference 
between the ranked eigenvalues from the two Eigen-analyses. The genome-wide 
distribution of these scores was standardized to yield a mean of zero and a 
standard deviation of one. In order to assign a varLD score to each region in our 
simulations, we located the window of 50 SNPs where the center of this window 
was nearest to the physical position of the simulated causal variant. When 
combining the association evidence across all three populations in our simulations, 
the composite varLD score has been defined as the sum of the varLD scores from 
the analyses of the three pairs of populations. The calculation of the varLD scores 
was performed on genotype data for Chinese, Malays and Asian Indians from the 
Singapore Genome Variation Project [69].  
For each simulated causal variant, we calculated the composite varLD score 
[23,90]. The varLD score quantifies the extent of LD differences in a genomic 
region between two populations, and we measure the composite varLD score as 
the summation of the three separate varLD scores from the three pairs of 
populations in our simulations.  
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We observed the region-based method yielded higher power than both SNP-based 
meta-analytic approaches when LD patterns were substantially differentiated 
across the three populations (Figure 17). In particular, the power difference 
between our method and the imputation approach was greatest in the 200 
simulated regions exhibiting the strongest evidence of LD variation. Given that 
the imputation in our simulations have been performed with reference panels that 
are ideal representations of the genetic diversity in the case-control data, the merit 
of our approach over the imputation approach is likely to be even greater in 
practice.  
Variable selection and quantifying phenotypic variance explained 
We assessed the proportion of phenotypic variance explained in the WTCCC type 
2 diabetes case-control samples using various combinations of SNPs that have 
been reported by the WTCCC [65], DIAGRAM+ [36] and from our analyses. 
Specifically, we fitted a logistic regression with the case-control samples, using 
only the specific combination of SNPs as explanatory variables in an additive 
fashion. We performed these assessments across different models that are listed 
below. To avoid the issue of co-linearity between the SNPs in each model, we 
fitted a full model with the SNPs in each of the stated models and performed a 
stepwise variable selection procedure using the Akaike’s Information Criteria 
(AIC), defined for each model as -2 maximized log likelihood + 2 # parameters. 
The proportion of phenotypic variance explained was evaluated in each model 
from the SNPs that remained after the variable selection procedure. This is 
quantified as  
[Deviance (Null model) – Deviance (Fitted model)] / Deviance (Null Model), 
where the null model refers to the logistic regression model with only an intercept 
term, and the deviance is quantified as -2 × log-likelihood of the model. The four 
models are fitted: 
i) with the 3 index SNPs reported by WTCCC with P-value < 5  10-7, of 
which all 3 SNPs remained after variable selection;   
ii) with the 56 index SNPs reported by WTCCC and DIAGRAM+  (see 




iii) with the 694 SNPs within the 5 regions that emerged in the region-
based meta-analysis (see Table 6 of the main text), of which 179 SNPs 
remained after variable selection; 
iv) with the 213 SNPs that remained after variable selection from (ii) and 
(iii), of which another round of stepwise variable selection resulted in 
203 remaining SNPs. 
We observed that the phenotypic variance in the WTCCC T2D samples increased 
from 1.57% when only the three loci from the original WTCCC publication was 
considered, to 5.43% when we included the 56 SNPs, and to 13.25% when we 
included SNPs (that remains after the stepwise variable selection step) from the 
five loci in our region-based analyses (Table 11). It is important to emphasize that 
the final calculation has been performed in the validation samples from WTCCC, 
even though the SNPs have been identified during the region-based screening 
with the four Singapore GWAS, which minimizes the effects of over-fitting. This 
suggests there is actually information in current GWAS for explaining at least part 
of the missing heritability, but tapping on this information requires different 
statistical strategies to identify the associations. This is consistent with the 
findings by the International Schizophrenia Consortium that extending the 
variance estimation to include SNPs that display weaker statistical evidence is 
able to explain a significant portion of the phenotypic variance [91]. Our method 
provides a statistical framework for capitalizing on these weaker but potentially 
genuine association signals.  
Gene-based and pathway-based analysis of T2D  
Results of the discovery gene-based meta-analyses were largely similar to those 
from the region-based analyses, although only CDKAL1 successfully replicated in 
the WTCCC gene-based analysis (Table 12). The pathway analysis using the 
gene annotations from the KEGG database [66-68] discovered four pathways 
exhibiting P < 0.05 in at least two populations (Table 13). Of these pathways, the 
adherens junction pathway remained statistically significant after Bonferroni-
correction for 212 pathways (Pdiscovery = 4.1  10-4, Pvalidation = 9.0  10-5).  The 
discovery of the association between this pathway and T2D onset is intriguing, as 
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the adherens junction pathway directly interacts with insulin signaling and is 
primarily targeted by drugs that modulate insulin binding to insulin receptors. 
Information on adherens junction pathway 
The adherens junction pathway is primarily mediated by molecules Nectin and 
Cadherin, and appears to be strongly associated with growth factor signaling, cell-
cell adhesion and preserving normal cellular architecture via accurate layering of 
epithelial cells and anchoring of the actin cytoskeleton. Dysregulation of this 
pathway has been strongly implicated in malignant transformation of otherwise 
benign tumors as well as the acquiring of metastatic ability [92,93]. Of note, 
Cadherin mediates in insulin signaling via the insulin and insulin-like-growth 
factor 1 receptors [94] (INSR and IFG1R).  
The efficient secretion of insulin from pancreatic beta-cells requires extensive 
intra-islet, cell-cell communication, and it has been shown that E-cadherin 
establishes and maintains epithelial tissues such as the islets of Langerhans; 
antibody blockade of E-Cadherin reduces overall insulin secretion from 
pancreatic cells [95]. Taking these accreted pieces of evidence together suggests 
the involvement of the adherens junction pathway and T2D susceptibility by 
impacting insulin action in a quantitative manner.   
The information on the adherens junction pathway can be obtained from KEGG 
online database http://www.genome.jp/dbget-bin/www_bget?pathway+hsa04520. 
A pathway map of the adherens junction pathway is illustrated in Figure 18.  
As the adherens junction pathway consists of a collection of 76 genes, it is of 
interest to investigate which genes contribute to the pathway-based association 
signals. More importantly, it is of interest to investigate whether similar genes are 
contributing to the pathway signals in the discovery populations and in the 
validation population. We observed that the genes that contributed to the 
pathway-based signal in the discovery meta-analysis were remarkably similar to 
the genes that contributed to the validation signal in the WTCCC T2D pathway-
based survey (Table 14). Of the 18 and 14 genes that contributed to the discovery 
and validation signals respectively, 10 were common to both discovery and 
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validation arms of the analysis. This suggests that the same biological mechanism 
as driven by the set of common genes may underpin the adherens junction 
pathway association with type 2 diabetes. 
Gene-based evidence at 41 established loci for T2D 
We additionally surveyed the gene-based evidence in the Singapore T2D GWAS 
and the WTCCC T2D study for the 41 genes that have been established in the 
T2D literature[36,55,59,71,73,74,96]. We observe that 10 of the 41 regions 
displayed gene-based P-value < 0.05 in the WTCCC dataset, of which 5 had P-
value < 0.001 and 2 had P-value < 10-8 (Table 15). In contrast, between 2 to 6 
genes exhibited gene-based evidence of P-value < 0.05 in the different Singapore 
GWAS scans. This is likely to be attributed mainly to a larger sample size of the 
WTCCC study, with 2000 cases and 3000 controls, as compared to ~1000 cases 
and ~1000 controls in each of the Singapore experiments.   
Buffer size comparisons for gene-based analysis 
For the gene-based analysis, a buffer is added to the flanks of each gene to capture 
the effects of regulatory elements that are not within the start and end coordinates 
of the gene, as well as SNPs that are outside the gene but are in LD with 
functional polymorphisms located within the genes. To assess the effect of the 
size of this buffer region, we performed an additional comparison on the evidence 
from the gene-based analysis of the WTCCC T2D data, using two buffer sizes of 
100kb and 200kb respectively. We noticed the evidence from the gene-based 
analyses were mostly robust to the choice of the buffer sizes, although for smaller 
genes, we observed the use of a larger buffer size appeared to increase the 
strength of the evidence (Figure 19). As smaller genes are expected to encompass 
lesser number of SNPs, the amount of statistical evidence tends to be weaker even 
if there is an over-representation of independent SNPs with evidence of 
phenotypic association. Increasing the buffer size thus increases the baseline 
number of SNPs across the region interrogated, and our methodology provides the 
formal statistical framework to query whether there remains an over-
representation of associated SNPs across the larger region. However, it is 
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Table 8 Comparison of eigenvalue threshold in the regional analyses 
                  Eigenvalue 
threshold      
Type I error  
0.80         
(%) 
0.85       
(%)      
0.90      
(%) 
0.95      
(%) 
0.99      
(%) 
1E-03 84.5 86.9 89.4 90.7 92.7 
1E-04 77.6 81.2 84.6 87.2 90.1 
1E-05 71.3 74.2 79.1 83.0 88.0 
1E-06 63.5 68.0 73.5 78.3 84.9 
1E-07 55.3 62.2 68.8 74.9 81.5 
1E-08 50.1 56.0 63.5 70.1 78.4 
False Positive Rate 2.2 2.9 4.3 5.0 9.7 
 
Simulations were performed with HAPGEN assuming a causal variant that is present in 
all HapMap phase 2 panels. The case-control genotype data is subsequently thinned to the 
SNP content of Affymetrix 500K (CEU simulations), Illumina 1M (JPT+CHB 
simulations) and Affymetrix 6.0 (YRI simulations). The power/false positive rate is 
defined as the percentage of the 5,000 simulations where there is at least one region 
displaying a P-value < Type I error/Bonferroni-corrected P-value of < 0.05 within 150kb 
of either flanks of the causal variant.  
 
Table 9 Comparison of over-representation P-value threshold in the regional 
analyses         
                                   P-value 
threshold               Type I error 
0.05            
(%) 
0.01           
(%) 
0.001          
(%) 
1E-03 90.9 90.7 88.1 
1E-04 84.5 87.2 84.6 
1E-05 80.0 83.0 81.2 
1E-06 73.8 78.3 77.5 
1E-07 67.6 74.9 73.7 
1E-08 61.7 70.1 70.9 
False Positive Rate 10.1 5.0 1.5 
 
Simulations were performed with HAPGEN assuming a causal variant that is present in 
all HapMap phase 2 panels. The case-control genotype data is subsequently thinned to the 
SNP content of Affymetrix 500K (CEU simulations), Illumina 1M (JPT+CHB 
simulations) and Affymetrix 6.0 (YRI simulations). The power/false positive rate is 
defined as the percentage of the 5,000 simulations where there is at least one region 
displaying a P-value < Type I error/Bonferroni-corrected P-value of < 0.05 within 150kb 
of either flanks of the causal variant.  
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Table 10 List of 56 SNPs from DIAGRAM+ (table extracted and condensed from 
the DIAGRAM+ publication)  
 
* SNPs that remained after variable selection by stepwise AIC.   
SNP Chr Position P‐value OR CI(lower 95%) CL(upper95%) Nearby Gene
rs10923931* 1 120,319,482 6.52x10‐5 1.138 1.068 1.212 NOTCH2
rs11899863 2 43,472,323 1.04x10‐5 1.169 1.091 1.252
rs7578597* 2 43,586,327 4.47x10‐5 1.151 1.076 1.231
rs13081389 3 12,264,800 2.01x10‐7 1.242 1.145 1.349
rs1801282* 3 12,368,125 8.01x10‐6 1.148 1.08 1.219
rs6795735 3 64,680,405 8.35x10‐5 1.086 1.042 1.131
rs4607103* 3 64,686,944 2.34x10‐4 1.096 1.044 1.15
rs1470579* 3 187,011,774 2.17x10‐9 1.139 1.091 1.188 IGF2BP2
rs1801214 4 6,353,923 3.16x10‐8 1.128 1.08 1.176
rs10010131* 4 6,343,816 4.59x10‐7 1.11 1.065 1.155
rs10440833* 6 20,796,100 1.84x10‐22 1.251 1.197 1.307
rs7754840 6 20,769,229 3.11x10‐15 1.185 1.135 1.236
rs849134* 7 28,162,747 2.8x10‐9 1.129 1.085 1.175
rs864745 7 28,147,081 2.06x10‐8 1.121 1.077 1.165
rs3802177* 8 118,254,206 1.45x10‐8 1.149 1.095 1.206
rs13266634* 8 118,253,964 1.52x10‐8 1.149 1.095 1.206
rs10965250 9 22,123,284 1.23x10‐10 1.198 1.134 1.266
rs10811661* 9 22,124,094 1.45x10‐10 1.191 1.13 1.257
rs12779790* 10 12,368,016 6.75x10‐4 1.092 1.038 1.149 CDC123/CAMK1D
rs5015480* 10 94,455,539 1.33x10‐15 1.181 1.133 1.23
rs1111875 10 94,452,862 9.1x10‐15 1.172 1.126 1.221
rs7903146* 10 114,748,339 2.21x10‐51 1.398 1.339 1.459 TCF7L2
rs163184 11 2,803,645 6.82x10‐5 1.087 1.043 1.132
rs2237892* 11 2,796,327 2.7x10‐3 1.141 1.047 1.244
rs5215* 11 17,365,206 1.6x10‐5 1.093 1.05 1.139 KCNJ11
rs4760790* 12 69,921,061 3.56x10‐6 1.112 1.063 1.162
rs7961581 12 69,949,369 1.82x10‐5 1.106 1.056 1.158
rs11642841 16 52,402,988 3.4x10‐8 1.128 1.08 1.176
rs9939609* 16 52,378,028 8.65x10‐8 1.116 1.072 1.162
rs4430796 17 33,172,153 1.52x10‐6 1.139 1.08 1.201
rs757210 17 33,170,628 1.6x10‐4 1.115 1.054 1.179
rs1387153 11 92,313,476 9.96x10‐7 1.122 1.071 1.175
rs10830963 11 92,348,358 1.01x10‐6 1.129 1.075 1.185
rs7578326* 2 226,728,897 8.72x10‐7 1.115 1.068 1.165
rs2943641 2 226,801,989 6.62x10‐5 1.087 1.043 1.133
rs243021* 2 60,438,323 8.14x10‐6 1.094 1.052 1.139 BCL11A
rs4457053* 5 76,460,705 4.15x10‐8 1.162 1.102 1.226 ZBED3
rs972283* 7 130,117,394 1.82x10‐6 1.104 1.06 1.15 KLF14
rs896854* 8 96,029,687 1.23x10‐6 1.104 1.06 1.148 TP53INP1
rs13292136* 9 81,141,948 1.49x10‐6 1.2 1.114 1.292 CHCHD9
rs231362* 11 2,648,047 6.41x10‐6 1.11 1.06 1.161 KCNQ1
rs1552224 11 72,110,746 6.99x10‐6 1.131 1.072 1.194 CENTD2
rs1531343* 12 64,461,161 1.7x10‐7 1.201 1.121 1.285 HMGA2
rs7957197* 12 119,945,069 4.56x10‐7 1.136 1.082 1.195 HNF1A
rs11634397* 15 78,219,277 5.08x10‐6 1.107 1.06 1.157 ZFAND6
rs8042680 15 89,322,341 8.19x10‐6 1.102 1.056 1.15 PRC1
rs6709268* 2 3,058,146 8.61x10‐6 1.148 1.08 1.33 TSSC1
rs6442037* 3 46,904,550 4.72x10‐6 1.11 1.061 1.16 PTH1R
rs7674212* 4 104,208,348 1.7x10‐7 1.114 1.07 1.161 NHEDC2
rs1048709* 6 32,022,914 5.96x10‐6 1.125 1.069 1.183 CFB
rs7118472 11 86,833,159 6.15x10‐6 1.22 1.12 1.33 TMEM135
rs2288232 12 27,836,125 3.92x10‐6 1.112 1.063 1.163 KLHDC5
rs17795982* 14 24,602,523 1.72x10‐6 1.155 1.088 1.224 STXBP6
rs8057749* 16 77,015,972 9.36x10‐6 1.811 1.392 2.354 WWOX
rs9465871 6 20,825,234 3.34x10‐7 1.18 1.04 1.34 CDKAL1

















Table 11 Percentage (%) of phenotypic variance explained by the various disease 
models in the T2D case-control from WTCCC 
Models1 # SNPs before variable selection 
(# SNPs after variable selection) 
% variance 
explained 
3 WTCCC1 SNPs 3 
(3) 
1.57 
56 DIAGRAM+ SNPs 









Combining the SNPs after variable 
selection from the 56 DIAGRAM+ 








1 Using a stepwise variable selection procedure with the Akaike’s Information Criteria 
(AIC) on the logistic regression that considers additive effects of the SNPs.   
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Table 12 Results of the gene-based meta-analysis for type 2 diabetes 






Discovery – Single population Discovery – Combined Validation from WTCCC1 
Pop2 # hits3 # SNP4 P # hits3 # SNP4 P # hits3 # SNP4 P 









4.24  10-6 
1.15  10-7 
0.457 
14.8 119 6.08  10-12 0 22 1.000 









9.96  10-4 
1.00 
2.49  10-5 
9.6 115 1.29  10-6 4.3 18 1.83  10-5 










5.02  10-11 
7.73  10-6 
19.2 271 5.28  10-11 0 35 1.000 









2.60  10-2 
5.21  10-8 
9.69  10-10 
20.1 159 3.18  10-16 0 25 1.000 









9.37  10-4 
1.00 
1.43  10-4 
10.3 177 1.02  10-5 0.9 25 0.279 









8.55  10-4 
1.00 
9.50  10-6 
11.3 172 1.24  10-6 0.9 26 0.305 
1 The start and end positions of the genomic region containing consecutive windows with P < 0.001 in at least two of the populations (in bold). The start and 
end positions of the top 250kb window are shown in brackets. Subsequent columns show the evidence for the discovery populations in the top window.  
2 The four discovery populations abbreviated: C1 – SP2 on Illumina 610, C2 – SP2 on Illumina 1M, M – SiMES, I – SINDI.  
3 The effective numbers of independent SNPs with P < 0.01 after accounting for LD. 
4 The effective numbers of independent SNPs across the region after accounting for LD. 
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 Table 13 Results of the pathway-based meta-analysis for type 2 diabetes 
 
Pathway name1 
(KEGG entry number) 
Discovery – Single population Discovery – Combined Validation from WTCCC1 
Pop2 # hits3 # SNP4 P # hits3 # SNP4 P # hits3 # SNP4 P 












1.34  10-5 
1.96  10-2 












4.33  10-2 
0.282 
5.38  10-4 












1.10  10-2 
0.137 
1.80  10-4 
149.7 10471 1.92  10-5 16.5 1527 0.413 











8.25  10-2 
4.79  10-2 
1.91  10-2 
138.9 10670 1.53  10-3 9.3 1567 0.996 
 
1 The assigned pathway name in the KEGG database containing consecutive windows with P < 0.05 in at least two of the populations (in bold). 
2 The three discovery populations abbreviated: C – SP2 Chinese, M – SiMES Malays, I – SINDI Indians.  
3 The effective numbers of independent SNPs with P < 0.01 after accounting for LD.  
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CHAPTER5 – TRANS-ETHNIC FINE-MAPPING USING POPULATION-
SPECIFIC REFERENCE PANELS IN DIVERSE ASIAN POPULATIONS 
Introduction 
Despite the success of genome-wide association studies (GWAS) in identifying 
genetic variants that correlate with disease onset or severity [33], the persistent 
problem of missing heritability signifies that the identified variants present, at best, 
a modest contribution to the phenotypic variance [34]. The design of GWAS 
fundamentally relies on detecting proxy markers in the human genome, known as 
tagging single nucleotide polymorphisms (SNPs), which are correlated to the 
biologically functional variants. It has been suggested that part of the missing 
heritability relates to the imperfect relationship between the proxy marker and the 
functional variant.  Genetic association studies for low-density lipoprotein 
cholesterol [13] and age-related macular degeneration [14,15] have shown that the 
heritability explained by the causal variants was significantly higher than those of 
the proxy SNPs. 
Fine-mapping is the approach through which we identify these functional variants, 
or at least localize the genomic regions where the functional variants reside. This 
usually requires complementing the patchy representation provided by genotyping 
microarrays in GWAS with denser sequence-level data, such as those from the 
1000 Genomes Project (1KGP) [6,97]. However, the perception and strategy 
towards fine-mapping have evolved significantly.  
An early study by Jallow and colleagues in localizing the haemoglobin S (HbS) 
variant in a malaria GWAS in The Gambia suggested that targeted sequencing of 
an implicated gene in a handful of population-specific individuals can provide a 
representative haplotype map that allowed accurate imputation to isolate the 
functional variant, which the use of an inappropriate haplotype map failed to 
achieve [17]. Unfortunately, the presence of long-range linkage disequilibrium 
(LD) in most non-African populations meant there were numerous perfect 
surrogates that were virtually indistinguishable from the functional variants, thus 
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compounding the quest to localize the causal variants [2,39]. Several reports then 
advocated the prospect of using different LD patterns intrinsic to multiple 
ancestries to overcome the challenge of long LD [11,22,23], although identifying 
causal variants with certainty proved elusive even with this strategy of trans-
ethnic fine-mapping, as seen in a recent report for Type 2 diabetes [98]. 
 
The 1KGP supplied whole-genome sequence-level data for more than 25 
populations from major ancestry groups globally.  Statistical imputation against 
this reference panel produced in silico sequence-level information for the GWAS 
data at almost no additional cost [16,62,99,100] and it was felt that this approach 
will provide greater resolution in our fine-mapping effort while mitigating the 
need for most populations to perform their own targeted or whole-genome 
sequencing.  One concern in using these reference panels is the knowledge that 
the HbS variant was not identified as the functional variant associated with 
malaria when a non-population specific reference panel was used.  This raises the 
question whether judicious use of population-specific reference panels will 
enhance our ability to localize functional variants through fine-mapping. 
 
In this study, we performed a systematic evaluation of the merit of trans-ethnic 
fine-mapping with GWAS data from three ancestry groups in Asia, consisting of 
East Asian Han Chinese, Southeast Asian Malays and South Asian Indians 
residing in Singapore. The intention is to locate the functional variants 
underpinning the association between 176 genetic loci sieved from the NIH 
GWAS catalogue (www.genome.gov/gwastudies) [101] with either eye-related 
traits such as corneal curvature (CC), central corneal thickness (CCT), corneal 
astigmatism (CA) and optic disc area (ODA) [102-108];  or blood lipid 
measurements such as triglycerides (TG), high-density lipoprotein cholesterol 
(HDL-C) and low-density lipoprotein cholesterol (LDL-C) [57,109-112].  
 
Our study differs from previous trans-ethnic fine-mapping studies, as we possess 
haplotype reference panels for Southeast Asian Malays [20] and South Asian 
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Indians [21] that were generated from high-coverage whole-genome sequencing, 
thereby allowing us to examine the significance of population-specificity in 
imputation panels for fine-mapping. We thus set out to answer the following two 
questions: (1) assuming there exists a shared functional variant between these 
three ancestry groups, can a trans-ethnic strategy locate this causal variant with 
more resolution? (2) is there any advantage to the use of population-specific 
reference panels in fine-mapping functional variants, above and beyond the 
current strategy of using cosmopolitan panel from Phase 1 of 1KGP that 
constitutes 1,092 individuals from 14 populations?  
Materials and Methods 
Simulation Setup  
We used the HAPGEN program [53] with haplotype and recombination data from 
Phase 2 of the International HapMap Project [46] to simulate case-control data 
with pre-selected SNPs as the causal variants, in order to evaluate whether these 
variants necessarily exhibit the strongest association evidence. A total of 2,000 
SNPs that were polymorphic in all three HapMap panels but were not found on 
commercial microarrays were chosen as causal variants. For each SNP, 1,000 
cases and 1,000 controls were simulated for each ancestry panel assuming a 
multiplicative model with an allelic relative risk of 1.5. The simulated data was 
thinned to retain only the SNPs that were located on commercial microarrays, 
before being recovered by imputation with IMPUTE [62] against the respective 
HapMap reference panel. This allowed the association evidence at each causal 
variant to be ranked against neighboring markers located within 750kb. A detailed 
description of the simulation setup can be found in the Supplementary Material.   
GWAS cohorts 
Our study considered data from three independent genome-wide studies involving 
1,889 Chinese from the Singapore Chinese Eye Study (SCES), 2,542 Malays from 
the Singapore Malay Eye Study (SiMES) and 2,538 Asian Indians from the 
Singapore Indian Eye Study (SINDI) [54,113]. All samples haven been genotyped 
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on the Illumina HumanHap 610-Quad BeadChip. Two rounds of imputation have 
been carried out for each cohort with two different reference panels: (i) the 
cosmopolitan reference panel from Phase I of the 1KGP comprising 1,092 
samples from 14 populations; (ii) a population-specific panel built from the 286 
Chinese samples from 1KGP, or from deep whole-genome sequencing 96 
Southeast Asian Malays or 38 South Asian Indians respectively. Imputed SNPs 
with information ≥ 0.50 (estimated by IMPUTE) were retained for analysis 
[59,114]. Details of the quality control criteria for genotyping and imputation for 
each cohort, including correction for covariates, Hardy-Weinberg equilibrium, 
minor allele frequency threshold and SNP/sample call rate are outlined in Table 
16.  
Identification of trait-associated loci  
We identified 176 unique loci from the NIH GWAS Catalogue 
(www.genome.gov/gwastudies) [101] that were associated with either eye-related 
traits such as corneal curvature (CC), central corneal thickness (CCT), corneal 
astigmatism (CA) and optic disc area (ODA) [102-108];  or blood lipid 
measurements such as triglycerides (TG), high-density lipoprotein cholesterol 
(HDL-C) and low-density lipoprotein cholesterol (LDL-C) [57,109-112]. Several 
features of interest were recorded for each study: first author, journal, year of 
publication, genetic ancestry, sample size in GWAS stage, total sample size in 
replication stage, array genotyped, genomic control factor in GWAS stage (if 
available), use of imputed SNPs (Y/N) and number of genomic regions achieving 
genome-wide significance in the initial and final stage (Table 17). There was a 
GWAS for CCT that had been published using the cohorts from Singapore [115] 
that was absent from the GWAS catalogue, and we appended the loci reported in 
this study that achieved genome-wide significance. 
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Table 16 Summary of study-specific quality control, imputation and analysis 
STUDY Study Singapore Indian Eye Study (SINDI) 
Singapore Malay Eye Study 
(SiMES) 
Singapore Chinese Eye Study 
(SCES) 
  Ethnicity Singapore Indians Singapore Malay Singapore Chinese 
  Size  2538 2542 1889 
GENOTYPING Genotyping Array Illumina 610K chip Illumina 610K chip Illumina 610K chip 
Sample QC Call rate ≥ 95% ≥ 95% ≥ 95% 
  Exclusions Duplicates, sex mismatch and evidence for relatedness 
Duplicates, sex mismatch and 
evidence for relatedness 
Duplicates, sex mismatch and 
evidence for relatedness 
SNP QC Call rate ≥ 95% ≥ 95% ≥ 95% 
  MAF ≥1% ≥1% ≥1% 
  HWE p≥10-6 p≥10-6 p≥10-6 
IMPUTATION Filter proper-info ≥0.5  proper-info ≥0.5  proper-info ≥0.5  
  MAF ≥0.01 ≥0.01 ≥0.01 
  Software IMPUTE2 IMPUTE2 IMPUTE2 
  Reference Panel(i) 1000G ALL 1000G ALL 1000G ALL 
  Reference Panel(ii) SSIP SSMP 1000G ASN 
Analysis Software SNPTEST SNPTEST SNPTEST 
  Covariates age,gender, PC1,PC2,PC3 age,gender, PC1,PC2 age,gender 
Table 17 Please refer to the Excel spreadsheet available online (http://www.statgen.nus.edu.sg/~project/PopSpecRef.html) 
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Statistical analyses 
The analysis at each locus included SNPs within 200kb on either flanks of the 
reported index variant. Multiple regions defined within the same gene are 
combined into one single locus if the distance between the index SNPs is within 
100kb. MANTRA was used to perform the meta-analysis of the three GWAS 
cohorts, as it explicitly allowed for allelic heterogeneity between diverse 
populations and has been found to be more robust and possessed higher power in 
detecting and localizing causal variants over other fixed- and random-effect 
strategies [31].  Based on the number of SNPs considered (n=1204), we adopted a 
significance threshold of 4 x 10-5 as the criterion for discovery in the meta-
analysis of the three GWAS cohorts, which was equivalent to a log10 Bayes’ 
Factor (BF) of 3.38 in MANTRA, according to the conversion formula -log10(P-
value) = 0.85 + 1.05 log10BF established by Wang and colleagues between P-
values and BFs [11]. The proportion of phenotypic variance explained by the 
identified functional variants at each locus is estimated within a regression 
framework by considering the difference in the regression R2 values obtained with 
and without the including the SNPs. In order to derive the list of SNPs in the 99% 
credible set, MANTRA considered the posterior probability that a given SNP is 
the causal variant, conditional on the association evidence at the SNP. The 99% 
credible set is then derived by agglomerating the SNPs with the strongest 
evidence until the cumulative posterior probability exceeded 0.99. Functional 
variants are referred to as SNPs that influence a biological system that ultimately 
lead to the phenotypes. In this manuscript, functional variants are restricted to the 
non-synonymous variants only (missense, nonsense, frameshift, etc.).   
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Results 
Rank of the association signals at the causal variant 
There is a tendency to look for a ‘smoking gun’ signal when it comes to fine-
mapping, which relies on the premise that a single causal variant will emerge with 
the strongest evidence of phenotypic association, relative to all other neighboring 
markers. To illustrate how fallacious this belief is, we simulated 2,000 collections 
of 1,000 cases and 1,000 controls in each of three major ancestry groups from 
HapMap2 (i.e. Europeans, Africans, and East Asians), with each collection 
derived by randomly choosing a SNP that exists outside any of the commercial 
arrays but is present in all three population panels in HapMap2 as the causal 
variant. We then investigated how often single-population fine-mapping or trans-
ethnic meta-analysis rediscovered the simulated functional variant as the SNP 
with the strongest evidence. This experiment was deliberately designed with the 
ideal set-up, where the ancestry-specific reference panel used to simulate the case-
control data was the same one used to impute and recover SNPs which have been 
thinned away.     
 
Regardless of whether fine-mapping was attempted within a single-population 
setting or in a meta-analysis of all three case-control collections, the simulated 
functional variants did not always emerge as the SNP with the strongest statistical 
evidence (Figure 20). In fact, this happened only in 23% and 26% of the 2,000 
collections for the European and East Asian ancestries respectively. The causal 
variants exhibited the most significant evidence in 43% of the simulated African 
case-control collections and in 56% of the meta-analyses, where the higher 
proportions were likely due to gains from shorter LD blocks inherently present in 
African populations. The situation looked more promising when we modified the 
problem to whether the causal variant existed within the top 10 SNPs with the 
strongest association evidence, which occurred in at least 77% of the single-
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Trans-ethnic fine-mapping GWAS loci for eye traits and blood lipids 
The NIH GWAS catalogue contained 176 genetic loci from GWAS of eye traits 
and blood lipids with index SNPs exhibiting P-values < 10-5 [101] (see Table 17 
for a catalogue of these 176 loci). We searched these loci for association with the 
same traits in three GWAS conducted in Singapore on the Chinese (Singapore 
Chinese Eye Study, SCES), Malays (Singapore Malay Eye Study, SiMES) and the 
Indians (Singapore Indian Eye Study, SINDI). Each of the three cohorts was 
imputed against two haplotype reference panels: (i) the 1KGP Phase 1 panel with 
1,092 individuals from 14 populations; and (ii) a population-specific panel from 
whole-genome sequencing 286 Chinese, 96 Malays or 36 Indians respectively. 
We then attempted to identify the functional variants responsible for the 
association at these 176 loci using MANTRA [11], a Bayesian methodology that 
explicitly accounted for allelic heterogeneity between populations and was 
assessed to possess the highest power for trans-ethnic meta-analysis [31].  
 
Using a log10 Bayes’ factor (BF) of 3.38 as the Bonferroni-corrected threshold for 
the mean of 1204 SNPs in a region of 400kb length across all 176 loci, our meta-
analysis reproduced the associations seen at 26 loci with the respective 
phenotypes (Table 18), thus qualifying these loci to the next stage of causal 
variant fine-mapping. The index SNPs with the strongest evidence at these loci 
were all common (MAF > 5%) in the three cohorts, although only the index SNP 
(rs7412, a missense SNP) at TOMM40-APOE for LDL-C association was a 
functional mutation except this was already previously reported [116].  
 
When we expanded the search to the 10 most strongly associated SNPs at each 
locus, two other missense mutations were identified at the ABCA1 locus for HDL-
C (rs2230808) and CARD10 locus for ODA (rs9610775) (Table 19). Adjusting 
for rs2230808 in a conditional analysis at ABCA1 attenuated all neighboring 
signals including the index SNP in the trans-ethnic meta-analysis (from log10BF 
of 3.96 to -0.42), although this is unsurprising given the high LD between the 
index SNP and the missense SNP in all three populations (r2 ≥ 0.81, Figure 21). 
At CARD10, the missense SNP rs9610775 is in strong LD with the index SNP in 
the Indians (r2 = 0.80) but is only moderately correlated in the Chinese and the 
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Malays (r2 = 0.50 and 0.48 respectively), although the evidence at the index SNP 
decreased to a log10BF of -0.59 after conditioning on rs9610775 (Figure 22). 
Loci with evidence of multiple association signals 
Rarely are the genotype-level data from GWAS in multiple ancestries available 
for performing multiple iterations of conditional analyses, and our study provided 
a valuable opportunity to investigate whether there could be multiple independent 
signals at each reported locus, which may point to the presence of multiple causal 
variants. An iterative hierarchical approach was taken in the multiple conditional 
analyses, where the most strongly associated SNP identified from each iteration of 
the conditional trans-ethnic meta-analysis was added as a covariate, until the best 
SNP yielded a log10 BF < 3.38 (refer to method section for the threshold). This 
allowed us to identify six loci (Table 20), where five loci (ABCA1, ZNF259, 
LIPC and CETP for HDL-C and TOMM40-APOE cluster for LDL-C) possessed 
two distinct signals each; and COL5A1 for CCT possessed three signals each.  
 
Accounting for the presence of multiple signals at each locus can produce an 
average of 1.7-fold increase in the amount of phenotypic variance explained, 
compared to including only the top SNP (Table 20). The greatest increase in the 
explained variance was observed for HDL-C in the Chinese at ABCA1, which 
jumped from 0.44% to 1.37% after including rs1883025 with the best SNP in the 
unconditional analysis (rs1883023). The two SNPs were practically independent 





Table 18 26 loci with significant association evidence in the meta-analysis of the three Asian cohorts   












CA SUCLG2 rs4856867 3 67,549,438 A G 0.181/0.276/0.214 intron 3.719 NA 
CA PDGFRA rs7660560 4 55,134,394 A G 0.172/0.253/0.263 intron 3.816 NA 
CC MTOR rs113124929 1 11,240,111 G A 0.134/0.199/0.239 intron 12.573 NA 
CC RPL22P13 rs4864863 4 55,100,831 G A 0.186/0.256/0.258 intron 7.682 NA 
CCT COL8A2 rs96067 1 36,571,920 G A 0.476/0.407/0.364 unknown 9.656 NA 
CCT COL5A1 rs3132307 9 137,436,214 C G 0.389/0.404/0.450 intron 14.017 NA 
CCT PDE8A rs7165242 15 85,845,848 T G 0.527/0.449/0.447 unknown 6.255 NA 
CCT ZNF469 rs34715091 16 88,326,782 G A 0.187/0.320/0.399 unknown 14.626 NA 
ODA RPL39P13 rs1192419 1 92,080,059 A G 0.887/0.149/0.691 unknown 19.904 NA 
ODA ATOH7 rs3858144 10 70,011,354 C T 0.672/0.174/0.690 unknown 19.554 NA 
ODA UNGP1 rs1121635 16 51,647,562 A T 0.573/0.534/0.614 unknown 3.415 NA 
ODA CARD10 rs9610778 22 37,914,526 A G 0.180/0.258/0.260 intron 5.622 rs9610775 
HDL LPL rs2119690 8 19,859,539 A G 0.211/0.157/0.248 unknown 6.449 NA 
HDL ABCA1 rs2777802 9 107,569,337 T C 0.410/0.475/0.408 intron 3.958 rs2230808 
HDL ZNF259 rs651821 11 116,662,579 C T 0.256/0.290/0.204 untranslated-5 15.873 NA 
HDL LIPC rs2043085 15 586,80,954 C T 0.432/0.465/0.430 unknown 11.162 NA 
HDL CETP rs247616 16 569,89,590 T C 0.157/0.149/0.294 unknown 25.748 NA 
HDL LIPG rs9958734 18 47,118,398 C T 0.406/0.301/0.086 untranslated-3 6.069 NA 
LDL CELSR2 rs611917 1 109,815,252 G A 0.066/0.075/0.291 intron 5.641 NA 
LDL HMGCR rs6453131 5 74,644,706 G T 0.502/0.466/0.524 intron 6.831 NA 
LDL TOMM40 rs7412 19 45,412,079 T C 0.091/0.116/0.087 missense 42.436 rs7412 
           
Continue in the next page. 
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Table 18 26 loci with significant association evidence in the meta-analysis of the three Asian cohorts   













TG DOCK7 rs1168036 1 62,962,734 A G 0.247/0.288/0.474 intron 4.045 NA 
TG LPL rs78404258 8 19,881,058 G A 0.103/0.072/0.106 unknown 5.53 NA 
TG BUD13 rs651821 11 116,662,579 C T 0.256/0.294/0.204 untranslated-5 30.035 NA 
TG CILP2 rs73004951 19 19,695,228 T C 0.095/0.224/0.159 intron 6.015 NA 
TG APOE rs483082 19 45,416,178 T G 0.194/0.266/0.135 near-gene-5 10.83676 NA 
 
* Highest ranking function-altering SNP in the top 10 associated SNPs. An “NA” entry indicates there were no function-altering SNPs in the top 10 SNPs.  
# log10 Bayes’ factor (BF) of 3.38 is used as the Bonferroni-corrected threshold. 
 
Table 19 Functional proxies for the top ranking SNPs at ABCA1 and CARD10 
Trait Locus Chr Position rsID log10BF# Annotation Rank LD (r2)* 
HDL ABCA1 9 107,569,337 rs2777802 3.958 intron 1 0.89/0.88/0.81
107,562,804 rs2230808 3.732 missense 6 
ODA CARD10 22 37,914,526 rs9610778 5.622 intron 1 0.50/0.48/0.80
37,906,262 rs9610775 4.424 missense 10 
*The LD values followed the order of SCES, SiMES and SINDI 
 #log10 Bayes’ factor (BF) of 3.38 is used as the Bonferroni-corrected threshold.  
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Table 20 Independent association signals identified from conditional analyses 
Locus Chr rsID Annotation Effect Allele Freq* 






LD with conditioning 
SNP(s)*  log10BF
# 
COL5A1 9 rs3132307 intron 0.389/0.404/0.450 -- -- 14.017 2.55/2.55/0.94  
    rs12554217 intron 0.040/ 0.087/ 0.375 rs3132307 0.001/0.048/0.035 4.292 3.00/2.99/0.95 




ABCA1 9 rs2777802 intron 0.410/0.475/0.408 -- -- 3.986 0.44/0.19/0.21 
    rs1883025 intron 0.231/0.295/0.410 rs2777802 0.000/0.000/0.044 3.632 1.37/0.37/0.33 
ZNF259 11 rs651821 untranslated-5 0.256/0.290/0.204 -- -- 15.873 2.20/ 1.79/ 0.31   
    rs7396061 intron 0.326/ 0.296/ 0.305 rs651821 0.099/ 0.037/ 0.025 4.401 2.53/ 2.24/ 0.81 
LIPC 15 rs1532085 unknown 0.432/0.465/0.430 -- -- 11.162 1.03/ 0.84/ 0.54   
    rs1077835 near-gene-5 0.387/ 0.528/ 0.311 rs1532085 0.006/ 0.008/ 0.003 7.558 1.80/ 1.26/ 1.61 
CETP 16 rs247616 unknown 0.157/0.149/0.294 -- -- 25.748 2.72/ 0.95/ 4.90 
    rs158477 intron 0.512/ 0.412/ 0.378 rs247616 0.076/ 0.062/ 0.199 5.546 3.71/ 1.31/ 5.43 
TOMM40 19 rs7412 missense 0.091/0.116/0.087 -- -- 42.436 0.15/ 0.03/ 0.05   
    rs584007 near-gene-5 0.423/ 0.459/ 0.404 rs7412 0.135/ 0.099/ 0.142 3.637 0.18/ 0.04/ 0.07 
*At each locus, we list the most strongly associated SNPs identified from each iteration of conditional analysis (log10BF < 3.38). We report effect allele 
frequency, LD and cumulative variance explained in the following order: SCES/SiMES/SINDI. 
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Trans-ethnic fine-mapping narrows associated regions 
Our study has relied on locating functional variants amongst the top 10 SNPs at 
each locus. There is another statistically rigorous approach employed in 
MANTRA that identifies the list of SNPs at a locus, known as the “99% credible 
set”, which cumulatively confers a 99% chance of harboring the causal variant. 
As this assumes there is a single causal variant shared across multiple populations, 
the six loci with multiple signals were excluded from this analysis. We thus 
identified the 99% credible sets in each of the single-population fine-mapping, as 
well as in the trans-ethnic fine-mapping, and compared the number of SNPs and 
the size of the genomic region covered by the credible set (Table 21). In all but 
one region (APOE), trans-ethnic analyses reduced the number of variants in the 
99% credible set. The genomic intervals of the region spanned by the credible set 
also shortened considerably in most of the loci considered. The greatest reduction 
was observed at CELSR2 for LDL-C, where the interval was reduced from 400kb 
within individual populations to only 6kb after trans-ethnic analysis, and the 
number of SNPs in the credible set was reduced from several hundreds to only 
nine, although none of the nine SNPs alter function (Figure 23).   
Population-specific versus 1KGP cosmopolitan reference panel 
The two sets of imputation performed on each of the three GWAS cohorts 
provided the opportunity to assess whether the use of a larger cosmopolitan 
reference panel will produce different index SNPs at the 26 loci, compared to the 
use of population-specific panels that are significantly smaller in sample sizes. 
We observed that in 20 out of the 26 loci, the top index SNPs were different 
between the two sets of analyses, although most of these index SNPs were within 
the top 10 SNPs on either lists (Table 22).  
The only exception was the identification of rs7412 in TOMM40-APOE in the 
meta-analysis of the population-specific imputed data, which yielded a log10 BF 
of 42.4 compared to the 1KGP equivalent of 22.9 (Figure 24). Instead, the meta-










































h SNP is ind
 rs611917 is 
s according to
r2 ≥ 0.8 (red)









 of SNPs at
Indians (SIN
the statistica
icated by a c
indicated by t
 the extent o
; (ii) 0.6  r2





























, diamond or 
mond while 
quilibrium w




nd all gene a
browser.  
 BF by 20 
ort in the tra
his SNP wa
SR2, for th
sis of all thre
 with the log
triangle. In e
all remaining














 SNPs are 
SNP in six 





















 ≥ 0.8 (red);





 used if the 
ta Cruz ge
e extent of l
 (ii) 0.6  r2 
r2 < 0.2 (blue

























h the lead SN





 a circle or a
 by the Un
s are assign
P in six cate








 r2 < 0.4 
  102
Table 21 Properties of the 99% credible sets of SNPs at significant loci 
  
99% credible set for  
trans-ethnic fine-
mapping 
99% credible set for 
Singapore 
Chinese(SCES) 
99% credible set for 
Singapore Malay 
(SiMES) 
99% credible set for 
Singapore Indian 
(SINDI) 
Traits Chr Locus Top SNPs SNPs Interval(bp) SNPs Interval(bp) SNPs Interval (bp) SNPs Interval (bp) 
CA 3 SUCLG2 rs4856867 175 381,274 855 392,558 205 390,394 846 392,558 
CA 4 PDGFRA rs7660560 109 104,064 633 397,663 459 397,663 534 397,663 
CC 1 MTOR rs113124929 31 107,541 646 395,738 94 222,826 239 216,842 
CC 4 RPL22P13 rs4864863 108 77,138 572 398,741 115 81,761 325 398,225 
CCT 1 COL8A2 rs96067 8 14,473 347 412,589 313 412,589 23 81,170 
CCT 15 PDE8A rs7165242 82 123,807 503 398,043 279 398,063 463 395,868 
CCT 16 ZNF469 rs34715091 14 9,602 304 341,010 30 38,889 24 22,977 
ODA 1 RPL39P13 rs1192419 5 7,162 32 13,058 83 195,445 6 7,162 
ODA 10 ATOH7 rs3858144 28 46,645 158 229,792 147 103,646 24 53,748 
ODA 16 UNGP1 rs1121635 573 398,754 631 399,438 624 399,438 601 399,438 
ODA 22 CARD10 rs9610778 39 27,300 700 396,912 547 396,912 46 209,430 
HDL 8 LPL rs2119690 69 58,010 341 304,655 1,316 424,571 86 58,019 
HDL 18 LIPG rs9958734 11 63,270 112 174,921 1,109 421,106 1,191 421,807 
LDL 1 CELSR2 rs611917 9 6,756 534 403,529 249 397,578 434 384,041 
LDL 5 HMGCR rs6453131 34 251,791 1,020 430,814 568 430,521 569 430,531 
TG 1 DOCK7 rs1168036 193 233,119 1,068 658,589 839 659,423 1,073 659,663 
TG 8 LPL rs78404258 155 104,099 786 428,023 1,301 424,571 166 269,809 
TG 11 BUD13 rs651821 2 1,128 2 1,128 23 103,260 19 56,941 
TG 19 CILP2 rs73004951 5 21,330 760 402,517 724 402,517 768 402,517 
TG 19 APOE rs483082 5 19,959 818 405,467 18 29,144 2 2,483 
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Table 22 Comparison between population-specific and 1KGP cosmopolitan reference panels 
      Population Reference panel discovery 
Replication   
in 1000G 
ref 
Rank            
in 1KG ref 
1000G reference panel 
discovery 
Rank in 
Pop ref Concordance check 
traits chr Locus Top SNP log10BF# log10BF# Rank  Top SNP log10BF# Rank  
CA 3 SUCLG2 rs4856867 3.719 3.857 1 rs4856867 3.857 1 Yes 
CA 4 PDGFRA rs7660560 3.816 3.725 6 rs1565670 3.852 24 No 
CC 1 MTOR rs113124929 12.573 12.456 5 rs74225573 12.553 7 No 
CC 4 RPL22P13 rs4864863 7.682 7.101 47 rs1800813 7.615 4 No 
CCT 1 COL8A2 rs96067 9.656 8.569 1 rs96067 8.569 1 Yes 
CCT 9 COL5A1 rs3132307 14.017 14.103 3 rs3132309 14.218 2 No 
CCT 15 PDE8A rs7165242 6.255 5.925 8 rs7172789 6.123 11 No 
CCT 16 ZNF469 rs34715091 14.626 13.833 7 rs28411862 14.086 2 No 
ODA 1 RPL39P13 rs1192419 19.904 19.758 2 rs1192415 19.799 10 No 
ODA 10 ATOH7 rs3858144 19.554 17.76 22 rs9783176 19.7 4 No 
ODA 16 UNGP1 rs1121635 3.415 1.041 16 rs2647987 2.307 2 No 
ODA 22 CARD10 rs9610778 5.622 4.96 7 rs2092171 5.114 5 No 
HDL 8 LPL rs2119690 6.449 5.946 44 rs3208305 6.749 41 No 
HDL 9 ABCA1 rs2777802 3.958 3.704 5 rs2740480 4.107 5 No 
HDL 11 ZNF259 rs651821 15.873 14.678 2 rs662799 15.484 2 No 
HDL 15 LIPC rs2043085 11.162 10.708 2 rs1532085 11.25 2 No 
HDL 16 CETP rs247616 25.748 25.226 5 rs3764261 25.565 4 No 
HDL 18 LIPG rs9958734 6.069 6.184 1 rs9958734 6.184 1 Yes 
LDL 1 CELSR2 rs611917 5.641 5.395 1 rs611917 5.395 1 Yes 
LDL 5 HMGCR rs6453131 6.831 7.257 3 rs10045497 7.41 0* No 
LDL 19 TOMM40 rs7412 42.436 22.931 9 rs72654473 44.675 4 No 
TRI 1 DOCK7 rs1168036 4.045 3.78 52 rs6693353 4.158 187 No 
TRI 8 LPL rs78404258 5.53 4.875 53 rs287 6.099 5 No 
TRI 11 BUD13 rs651821 30.035 31.437 1 rs651821 31.437 1 Yes 
TRI 19 CILP2 rs73004951 6.015 5.368 1 rs73004951 5.368 1 Yes 
TRI 19 APOE rs483082 10.837 9.859 3 rs438811 10.75 21 No 
* Rank 0 means the variant is not found in the population-specific MANTRA result.        
#log10 Bayes’ factor (BF) of 3.38 is used as the Bonferroni-corrected threshold. 
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Discussion 
There have been several efforts to locate the functional variants driving GWAS 
signals with and without the use of data from diverse genetic ancestries [11,23]. 
These studies have relied on the causal variants emerging with the strongest 
evidence of association, as was seen in fine-mapping the sickle cell variant in the 
malaria study conducted in The Gambia [17]. However, we have shown, in our 
simulations, that even in the scenario where the GWAS was imputed against a 
population-specific reference panel, the functional variant did not emerge as the 
top ranking SNP in about 50% of the simulations even after combining data from 
diverse ancestries. Our attempt to fine-map causal variants at loci associated with 
eye traits and blood lipids identified only three possible functional candidates out 
of 26 eligible loci. The truth is fine-mapping is considerably more challenging 
than first anticipated, and the strategy to simply rely on meta-analyzing data from 
existing GWAS imputed with reference haplotypes from 1KGP is unlikely to be 
successful. Already our study has shown how fine-mapping evidence can 
decrease by almost 20 orders of magnitude due to the inadvertent exclusion of a 
possible missense SNP as a result of imperfect imputation in one cohort using the 
cosmopolitan panel. This alone suggests that for a process as sensitive as fine-
mapping, the use of population-specific panels can be important, more so because 
it is almost impossible to predict or detect when a cosmopolitan panel will fail.   
 
There were several reasons why the fine-mapping success at HbS was exceptional: 
(i) the variant confers almost ten-fold protection against severe malaria, which is a 
condition often fatal for young children in impoverished health systems [17]; (ii) 
ongoing balancing selection between sickle cell anemia and severe malaria 
resulted in the presence of a single long haplotype in The Gambia that carried the 
protective allele (measured by a high D’ of 1.00); (iii) the shorter LD blocks 
inherently present in African populations (measured by a low r2) [117]; and (iv) 
convergent evolution of the HbS locus resulted in the protective allele residing on 
fundamentally different haplotype backgrounds in different populations [118]. 
None of these four conditions were likely to be present for functional variants 
driving non-communicable diseases and common traits.  
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Our study showed that multiple independent signals at each associated locus 
identified through conditional analyses could increase the amount of phenotypic 
variance explained. Thus, using a single index SNP to estimate genetic heritability 
at each locus, will underestimate the contribution of these genetic. However, there 
are significant operational challenges in performing multiple iterations of 
conditional analyses in a large multi-study meta-analysis, as researchers typically 
share only GWAS summary statistics and not the genotype-level data necessary 
for conditional analyses. Deconvoluting multiple independent signals to identify 
the underlying functional variants also increase the complexity, although this 
offers the opportunity for novel statistical methodologies to be developed, such as 
CAVIAR by Hormozdiari and colleagues that explicitly aims to identify multiple 
causal variants within a single locus [119].  
 
Many studies have reported that population-specific panels, even if they are 
considerably smaller in sample size, can yield higher imputation accuracy than 
with the 1KGP panel [17-19]. Contrary to the perception that this is only true in 
populations not represented in the 1KGP, a recent study by the Genome of the 
Netherlands (GoNL) Consortium reported significantly better imputation over 
1KGP of low-frequency and rare variants with a population-specific panel built 
by sequencing 769 Dutch individuals [18]. It is thus important to contextualize 
previous reports that a well-defined cosmopolitan panel can provide accurate 
imputation of unobserved variants, even for those with low allele frequencies 
[16,47,120]: these studies usually rely on statistics on imputation performance 
that are averaged across the whole genome, and knowledge of these statistics may 
only be peripherally useful when deciding whether a specific genomic region has 
been accurately imputed. Do we even know how common the scenario is where a 
functional variant is excluded from a trans-ethnic meta-analysis, simply because 
the imputation accuracy failed to meet some pre-determined threshold and was 
thus filtered out in one of the contributing GWAS?  
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The cost of whole-genome sequencing is dropping rapidly, and it is entirely 
plausible that future association studies will rely on whole genome sequencing 
instead of genotyping surrogates. However, the challenge provided by long 
stretches of high LD will almost certainly remain to confound the search for the 
causal variants. Trans-ethnic strategies can continue to provide a viable solution 
by leveraging on diverse LD patterns. Perhaps what is promising about this then is 
that imputation will no longer be required to fill in the blanks, which comes with 
the real risk that we exclude the very variant that we are looking for.    
Supplementary Material 
Simulation to test for the rank of association signals at causal variant  
Case-control data were simulated using the HAPGEN program with reference 
data from phase 2 of the International HapMap Project. We randomly selected 
2,000 SNPs that are present in all three HapMap population panels but not on any 
of the popular genotyping platforms from Affymetrix and Illumina (Affymetrix 
500K, Affymetrix 6.0 and Illumin1M) as causal variants. For each causal variant, 
we simulated 1000 cases and 1000 controls in each of the CEU, JPT+CHB and 
YRI panels by assuming a multiplicative disease effect equivalent to an allelic 
relative risk of r at the minor allele of the causal variant, with r = 1 for assessing 
false positives and r = 1.5 for evaluating statistical power (see Supplementary 
Material for power simulations when r = 1.3). Genotype data for SNPs located 
within 750kb on either flanks of the causal variant were simulated in each 
HapMap panel. To mimic the scenario where experiments involving different 
populations utilized different genotyping technologies, we thinned the simulated 
CEU case-control genotypes to only the SNPs that are located on the Affymetrix 
500K array. The JPT+CHB and YRI data were reduced to the SNPs found on the 
Illumina 1M and Affymetrix 6.0 arrays respectively. To compare against the ideal 
scenario that appropriate population-specific haplotype panels are available for 
imputation against, we ran IMPUTE (Marchini, et al., 2007) on the thinned 
genotype data from each population with the corresponding HapMap reference 
panel although we excluded the simulated causal variant to represent an 
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incomplete reference panel. This statistically infers the genotypes of the removed 
SNPs. Frequentist tests for additive disease association are performed with 
SNPTEST on the thinned genotype data and the imputed SNPs, with analyses of 
the latter incorporating the additional feature in SNPTEST that averages across 
imputation 
uncertainty(http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html). 
The recommended effective population sizes of 11,418, 14,269 and 17,469 were 
adopted for CEU, JPT+CHB and YRI respectively during the HAPGEN 
simulations and the imputations with IMPUTE (Marchini, et al., 2007). 
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CHAPTER 6 – TRANS-ETHNIC FINE-MAPPING OF RARE CAUSAL 
VARIANTS 
Introduction 
GWAS have achieved great success in identifying genetic variants that are 
associated with complex disease and human traits. To date, there are more than 
four thousand genetic variants reported with genome-wide significant evidence in 
more than 1,500 publications, according to the US National Human Genome 
Resource Institute (NHGRI, http://www.genome.gov/gwastudies/). Despite these 
remarkable successes, the identified variants only explain a small proportion of 
the trait heritability, such as height where only 5% of phenotypic variance has 
been explained by the identified loci despite a heritability estimate of 80% [121].  
 
Designed on the basis of the Common Disease-Common Variant hypothesis, that 
complex disease or human trait susceptibility is modestly influenced by genetic 
variants that are present in the population with minor allele frequency (MAF) 
exceeding 5% [25-27], GWAS fundamentally relies on the presence of genetic 
correlation to survey the human genome in an efficient manner. By focusing on 
well-defined “tags” that are representative markers of the information content in 
the neighboring genomic regions, LD allows >80% of the common variants in the 
human genome to be summarized by around one million SNPs. Discoveries of 
genotype-phenotype associations to date have thus been made with these tagging 
SNPs where the SNPs by themselves are not necessarily functional. The 
underlying causal variants that are biologically responsible for phenotype 
variation are seldom assayed directly, and in most situations, still unknown. While 
several reports have suggested that identifying the causal variants can increase the 
amount of heritability explained [13,122], it is increasingly clear that the 
Common Disease-Common Variant hypothesis is unlikely to fully explain the 
genetic etiology to diseases and traits.  
 
The focus has since shifted to functional variants that are present at lower 
frequencies in the population, broadly defined as low-frequency (MAF is between 
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1% and 5%), or rare (MAF < 1%), although these are discussed together in this 
chapter. These variants are expected to contribute to common diseases by exerting 
larger effects on the phenotype, such that these variants contribute to explain a 
modest degree of phenotypic variance, despite their low-frequencies in the 
population (see Table 23). For example, Tang and colleagues reported a variant 
rs17863783 with a risk allele frequency of 2.5% in 5,284 healthy controls and an 
odds ratio of 0.55 for bladder cancer risk [123]; and a report by Nejentsev and 
colleagues that identified four rare variants with almost a two-fold reduction in 
type 1 diabetes risk through re-sequencing the IFIH1gene that was initially 
implicated by GWAS [29]. The latter study demonstrates the importance of 
surveying across the whole allelic spectrum: from common variants with small or 
modest effects, to low-frequency or rare variants with moderate to large effects, in 
order to understand the genetic contributions to complex diseases and common 
traits.    
Table 23 Population genetic characteristics of common and rare variants 
 
Characteristics Common Variants Rare Variants 
MAF threshold > 5% < 1% 
Time of mutation Ancient Recent 
Expected effect size1[124] Moderate 
1.0 < RR < 2.0 
 < 0.4 
Large 
RR > 2.0 
 > 0.4 
Allele sharing Shared across multiple 
populations 
Usually population-specific 
LD structure High LD (r2 > 0.8) with 
neighboring common 
variants 
Weak LD (r2 < 0.3) with 
neighboring variants 
1 RR stands for relative risk, which is relevant to case-control studies, while  indicates 
the standardized difference of a quantitative trait between carriers of the two allele 
 
Fine-mapping of causal variants 
Leveraging on the presence of LD has allowed GWAS to survey most of the 
genome by genotyping a smaller subset of well-chosen tag SNPs. However, the 
selection of these SNPs prioritizes their ability to summarize the information of 
their neighboring variants, rather than on the biological significance of the SNPs. 
GWAS thus identify indirect associations, where the SNPs discovered to be 
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associated with the phenotype are not biologically meaningful by themselves but 
are simply correlated to the underlying (and often unknown) functional variants. 
Given that the real aim of a genetic association study is to identify the genomic 
unit (either the gene, or the specific SNP within a gene) that causes a biological 
change to produce an impact on the phenotype, there is a need to follow up on the 
discoveries made by GWAS to localize these functional units. This process is 
known as fine-mapping the causal variants, which can either mean to identify the 
exact functional polymorphisms or to narrow the genomic region where the 
functional polymorphisms may reside.   
 
There are two general approaches to the process of fine-mapping: (i) through 
targeted re-sequencing of a candidate region which, with sufficient sequencing 
coverage, is expected to locate most of the polymorphic positions in the region, 
and these can subsequently be tested for association with the phenotype; (ii) 
through in silico genotyping or genotype imputation with well-chosen reference 
haplotype panels obtained from either targeted or whole-genome sequencing of a 
set of population samples, which will infer the genotypes for the variants that are 
present on the haplotype panels for subsequent testing of association with the 
phenotype [28]. The expectation in both approaches is that the functional 
polymorphism will present the strongest signal, or be amongst the top signals. An 
example of the latter fine-mapping strategy was demonstrated by Jallows and 
colleagues, where the classic functional variant for sickle cell anemia (rs334 at 
5,248,232bp on chromosome 11) was successfully localized by imputing 2,500 
severe malaria cases and controls off a population-specific reference panel built 
from targeted re-sequencing a 111kb region surrounding the GWAS findings in 
62 additional samples [17].  
Trans-ethnic fine-mapping of common causal variants 
The principle of fine-mapping relies on segregating the causal variant(s) from 
other SNPs that are not functionally relevant with respect to the phenotype. For 
common variants, long stretches of LD paradoxically confound the process of 
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Due to different evolutionary and migration history, LD structure can vary 
significantly across populations, particularly between those from different 
ancestries [125]. Assuming that the causal variant is functional and shared across 
populations of different ancestries, there is the opportunity to leverage on varying 
patterns of genetic correlation between populations in order to localize the causal 
variant. This can happen in two manners: (i) the functional allele at the causal 
SNP resides on several distinct haplotypes in different populations, and few SNPs 
will display consistent evidence of phenotypic association across multiple 
populations upon harmonizing the fine-mapping evidence from these populations; 
(ii) the functional allele at the causal SNP resides on one main haplotype that is 
present across different population, except the strength and extent of LD between 
the causal variant and the surrogate SNPs on this haplotype differs between 
populations, and harmonizing the fine-mapping evidence narrows the genomic 
region to the intersection of the different haplotype lengths [28] (Figure 25).   
Trans-ethnic fine-mapping of rare causal variants 
There have been numerous reports of success in the use of trans-ethnic strategies 
to localize the causal variants from GWAS discoveries [28,126-128]. Whether 
this process can be similarly extended to localize low-frequency, or rare causal 
variants, remains to be seen. Here, we present an overview of the situations that 
facilitate the process of trans-ethnic fine-mapping of common causal variants and 
discuss the parallel situations for rare variants (Table 24).   
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Table 24 Comparisons between trans-ethnic fine-mapping of common and rare causal variants 
Conditions for trans-
ethnic fine-mapping 
Common causal variants Rare causal variants 
1. Presence of a causal 
variant across populations 
from different genetic 
ancestries 
Likely to be an older mutation, thus present and 
functional across populations from different 
genetic ancestries  
Likely to be more recent, thus tend to be 
ancestry- or population-specific, where the same 
SNP may be causal in one population but 
monomorphic or not functional in other 
populations 
2. Method of discovering 
and quantifying genetic 
association 
Each SNP is typically the unit of analysis and 
association testing measures the evidence of each 
SNP to be linked to the phenotype of interest 
While SNP-based analyses are performed as with 
common variants, the typical unit of 
measurement aggregates the allele counts across 
multiple SNPs in a region to measure genetic 
burden, thus presenting a region-based evidence 
3. Linkage disequilibrium 
(LD) between a causal 
variant and neighboring 
SNPs 
Likely to be in LD with neighboring SNPs, and 
these SNPs present evidence of similar 
magnitude as the causal variant 
Likely to be in weak or impractical strength of 
LD with neighboring SNPs due to low frequency 
of the functional allele 
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(i) Presence of a causal variant across populations of different ancestries 
The fundamental concept of trans-ethnic analyses assumes that the same genetic 
unit, whether it is a SNP, a gene exon, or the entire gene itself, is biologically 
responsible for altering the expression of the phenotype across the different 
populations that are being jointly analyzed. For common causal variants, this 
assumption is likely to be valid given that these mutations tend to be older and 
would have occurred prior to the divergence of these different populations [129].  
 
In contrast, rare SNPs are more likely to be recent mutations and thus ancestry- or 
even population-specific [129]. This presents a significant challenge in attempts 
to pool the evidence of phenotypic association at a rare SNP, since the SNP may 
be polymorphic and functional in one population, but may be monomorphic in the 
remaining populations, and the joint analysis attenuates rather than strengthens 
the statistical evidence [125].  
 
The 1000 Genomes Project provided vital insights to the distribution of 
polymorphic SNPs across global populations. Through whole-genome sequencing 
of more than 2,500 individuals from at least 20 population groups around the 
world, the 1KGP presents an unbiased survey of genetic variation across diverse 
populations. One of the crucial findings that is relevant to determine the success 
of trans-ethnic association analyses is on the specificity of polymorphisms 
according to MAF. The 1KGP reported that common variants with MAF 
exceeding 10% are shared across almost all the populations in Phase I of the 
project, whereas only 17% of the rare variants are present in populations within 
the same ancestry group; and 53% of the rare variants with MAF < 0.5% are 
population-specific [97]. This finding suggests that, while trans-ethnic analyses of 
rare variants may be realistic for populations from the same ancestry, it is unlikely 
to be feasible to extend this to multiple populations from diverse ancestries.  
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(ii) Method of discovering and quantifying genetic associations 
A GWAS typically analyses each SNP independently for evidence of phenotypic 
association. The strength and direction of the association is similarly quantified at 
the SNP level, measuring the impact of each additional copy of the minor allele in 
altering phenotype. This relies on standard statistical procedures such as analysis 
of variance (ANOVAs) or regression analyses, or univariate approaches such as 
chi-square tests or t-tests of averages. These approaches have proven to be 
reasonably successful in locating bona fide associations with common variants.  
 
However, the statistical ability of these methods to successfully detect evidence of 
phenotypic association depends on observing sufficient number of samples that 
are carrying particular copies of the two alleles. These approaches are thus poorly 
powered to measure the evidence at rare variants, where the number of samples 
carrying the risk allele may be very small. For example, Asimit and Zeggini 
illustrated, through a series of simulations, that as the causal allele frequency 
decreases from 5% to 1% to 0.1%, the sample size required to attain a power of 
80% to detect an allelic odds ratio of 2 at the accepted genome-wide significance 
level of P = 5 × 10-8 increases from 2,500 to 12,000 to 117,000 [130]. As a result, 
analyses of rare variants for phenotype association typically aggregate the 
cumulative impact of multiple SNPs located in a contiguous genomic region, for 
example by pooling the number of copies of rare alleles within a phenotype 
stratum. 
 
The underlying assumption for genetic burden test is that the set of rare variants 
within a region collectively influence the disease susceptibility, and the statistical 
evidence is measured according to whether the rare alleles tend to be more 
specific to subjects in a phenotype classification. However, methods such as the 
Cohort Allelic Sum Test (CAST) [131], the Weighted Sum Test (WST) [132], and 
the collapsing regression method [133], tend to ignore the direction of the effects 
of the rare alleles, and these tend to lower the power of the aggregated allele 
counts to correlate with phenotype expression, since rare alleles from different 
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causal variants may be deleterious or beneficial. The Sequence Kernel 
Association Test (SKAT) [134] properly accommodates for the direction of the 
effects of rare alleles, and has been shown to possess higher statistical power than 
most of the collapsing approaches.  
 
For a genomic region that genuinely harbors causal variants across multiple 
populations, pooling the evidence from individual SNPs is unlikely to improve the 
strength of the statistical association, since the architecture of rare variants 
suggests that different rare causal variants in the same region are likely to be 
present across the different populations. However, given that the unit of analysis 
for rare variants typically interrogates the entire genomic region; trans-ethnic 
analyses can boost the ability to locate these associated regions by aggregating the 
statistical evidence of phenotypic association (Figure 25). Identifying the rare 
causal variants in the emerging genomic region will require interrogating which 
SNPs contribute to the primary association signal within each population and by 
assessing the annotations – a process of fine-mapping that similarly is unlikely to 
benefit from trans-ethnic strategies.  
(iii)  Linkage disequilibrium between a causal variant and neighboring SNPs 
Causal variants with minor allele frequencies that are in excess of 5% are often in 
useful levels of LD with neighboring SNPs, and they tend to present similar 
evidence of phenotypic association as the causal variants. GWAS has relied on 
such long stretches of high LD in identifying the markers that correlate with 
phenotype expression. Trans-ethnic fine-mapping of these common causal 
variants is thus necessary to distinguish the surrogate SNPs from the causal 
variants.  
 
The situation is notably different for rare causal variants, as these tend to be in 
weak levels of LD with surrounding markers due to their low minor allele counts. 
From this perspective, there is no need to depend on trans-ethnic fine-mapping to 
localize rare causal variants, and often the causal variants can be identified by 
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interrogating the evidence within a population, as suggested by Zhu and 
colleagues who developed the “preferential LD” approach [135]. They suggested 
that weak levels of LD are present between a rare causal variant and a small set of 
markers that may be used to locate the genomic region, but such LD is still 
considerably stronger than those present between the causal variants and other 
surrounding SNPs. Based on this assumption, the “preferential LD” approach 
searches for rare variants with unexpectedly higher LD with the discovery variant, 
which are subsequently more likely candidates as the causal variants. When 
applied to a range of diseases, this approach successfully confirmed two well-
known rare causal variants for Crohn’s disease in the NOD2 gene [136], two non-
synonymous ITPA variants (rs1127354 and rs7270101) that cause ribavirin-
induced hemolytic anemia [137], and rare variants in UGT1A6 gene for bladder 
cancer [28].  
 
Conclusion 
Trans-ethnic fine-mapping has seen remarkable success in disentangling the 
conundrum of long stretches of high LD to either locate common causal variants, 
or at least narrow the genomic region where these functional variants at MAF > 5% 
can be found. However, the genetic architecture of rare variants is considerably 
different from that of common variants without the complication introduced by 
LD. For common causal variants, it appears existing methods are more than 
adequate to locate and validate an association signal, and the challenge lies in 
identifying the genuine causal variants from perfect surrogates. For rare variants, 
the greater challenge appears to lay in locating and validating an associated 
genomic region, rather than in fine-mapping the causal variants. Indeed, once a 
genomic region has been systematically confirmed to be associated with a 
phenotype, fine-mapping the causal variants is unlikely to require more than the 
careful interrogation of which rare SNPs contributed to the association signal and 




CHAPTER 7 - CONCLUSIONS AND DISCUSSIONS 
The last 10 years have been the era of genome-wide association studies. Vast 
efforts have been expanded to look for genetic variants that are associated with 
complex diseases and human traits, although the amount of phenotypic variation 
explained remains moderate at best. This thesis has focused on the studies of two 
primary statistical approaches: i) the global meta-analysis that extends the 
identification of novel genetic variants, through both SNP-based and region-based 
statistical approaches; ii) the trans-ethnic fine-mapping that localizes the real 
biologically functional variants for the phenotype of interest, targeted at both 
common and rare variants.  
Both meta-analysis and trans-ethnic fine-mapping require the pooling of GWAS 
studies from multiple populations, although the preferences over the level of LD 
diversity are contrary to each other. Meta-analysis requires similar LD structures 
in multiple populations to increase the sample size without introducing additional 
study heterogeneity; on the other side, trans-ethnic fine-mapping fundamentally 
relies on the LD diversity to differentiate the causal variants from the surrogate 
tagging SNPs. As such, a useful approach is to investigate whether there are any 
population diversity metrics that will be useful for identifying the populations or 
genomic regions where trans-ethnic approaches for meta-analysis and fine-
mapping are likely to be more efficient. Four metrics have been explored by the 
author and colleagues in a separate study and the results suggested that 
quantifying the average FST of the SNPs in the region or measuring the population 
specificity of haplotypes in the region is indicative of meta-analysis. For fine-
mapping of causal variants, assessing the degree of haplotype sharing and the 
extent of LD variation between populations are more informative [22]. Although 
this piece of work is not included in this thesis, it is indispensable in the study of 
trans-ethnic meta-analysis and fine-mapping.  
The study of both meta-analysis and trans-ethnic fine-mapping rely on imputation 
technology to complement the genotyping microarrays with denser set of 
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haplotype reference panels. The cosmopolitan panel is used in meta-analysis to 
harmonize the SNP contents in diverse populations. Population-specific reference 
panels are advocated for trans-ethnic fine-mapping to better reflect the genetic 
structure in each population. Although imputation is the most effective approach 
to estimate the information for untyped SNPs, it is unfortunately constrained by 
the imputation accuracy. Especially in the process of fine-mapping, small 
deviations in the genotype estimation can lead to a misidentification of the real 
causal variant. As the cost of whole-genome sequencing is dropping rapidly, 
imputation technology will gradually be replaced by direct sequencing of the 
whole genome with high accuracy. GWAS are expected to discover more 
phenotypic associated variants, not only common SNPs, but also rare variants and 
de novo mutations.  The focus of genetic studies should thus shift to interpretation 
and utilization of the GWAS discoveries.  
The two studies of trans-ethnic fine-mapping in this thesis have shown that the 
attempt to use purely statistical methods to identify the exact causal variant is 
unlikely to achieve success. Some scientists thus suggest focusing on defining 
generically applicable functional assays or workflows for chasing down causal 
variants within implicated haplotypes. Successful examples include the 
CRISPR/Cas9 system, where candidate causal variants for a given association are 
systematically introduced to a uniform genetic background in a relevant cell type 
for measuring the impact on the transcriptional output of nearby genes. More 
efforts need to be put in to the development of functional assays since the current 
work is limited by the fact that no standard statistical evidence can be defined and 
consistently applied. 
An alternative approach is to combine the GWAS findings with other information 
measured from the transcriptome, the proteome as well as the metabolome. For 
example, recent studies have reported that associations between loci such as 
FADS1, ELOVL2 or SLC16A9 and lipid concentrations have been explained by 
GWAS with metabolomics. There are limits on what we can learn from genetics 
alone. As we are entering an era of ‘personal genomics’ with additional ‘-omics’ 
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data available, we can merge them with the genetic data to achieve our goal to 
understand the genotype-phenotype relationship for the purpose of improving 
healthcare.  
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